Stock Code:3105

WIN SEMICONDUCTORS CORP. AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS

With Independent Auditors' Review Report For the Three Months Ended March 31, 2024 and 2023

Address: No.69, Keji 7th Rd., Hwaya Technology Park, Guishan Dist., Taoyuan City, Taiwan

Telephone: 886-3-397-5999

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

Table of contents

	Contents	Page				
1. Cov	er Page	1				
2. Tabl	e of Contents	2				
3. Independent Auditors' Review Report						
4. Cons	solidated Balance Sheets	4				
5. Cons	solidated Statement of Comprehensive Income	5				
6. Con	solidated Statement of Changes in Equity	6				
7. Cons	solidated Statement of Cash Flows	7				
8. Note	s to the Consolidated Financial Statements					
(1)	Company history	8				
(2)	Approval date and procedures of the consolidated financial statements	8				
(3)	New standards, amendments and interpretations adopted	8~10				
(4)	Summary of material accounting policies	$10 \sim 12$				
(5)	Significant accounting assumptions and judgments, and major sources of estimation uncertainty	12				
(6)	Explanation of significant accounts	12~50				
(7)	Related-party transactions	51				
(8)	Pledged assets	52				
(9)	Commitments and contingencies	52				
(10)	Losses due to major disasters	52				
(11)	Subsequent events	52				
(12)	Other	53				
(13)	Other disclosures					
	(a) Information on significant transactions	56~59				
	(b) Information on investments	60				
	(c) Information on investment in mainland China	61				
	(d) Information on major shareholders	61				
(14)	Segment information	54~55				



安侯建業群合會計師事務的 KPMG

台北市110615信義路5段7號68樓(台北101大樓) 68F., TAIPEI 101 TOWER, No. 7, Sec. 5, Xinyi Road, Taipei City 110615, Taiwan (R.O.C.) 電 話 Tel + 886 2 8101 6666 傳 真 Fax + 886 2 8101 6667 網 址 Web kpmg.com/tw

Independent Auditors' Review Report

To the Board of Directors of WIN Semiconductors Corp.:

Introduction

We have reviewed the accompanying consolidated balance sheets of WIN Semiconductors Corp. and its subsidiaries as of March 31, 2024 and 2023, and the related consolidated statements of comprehensive income, changes in equity and cash flows for the three months ended March 31, 2024 and 2023, and notes to the consolidated financial statements, including a summary of material accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standards ("IASs") 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of WIN Semiconductors Corp. and its subsidiaries as of March 31, 2024 and 2023, and of its consolidated financial performance and its consolidated cash flows for the three months ended March 31, 2024 and 2023 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

The engagement partners on the reviews resulting in this independent auditors' review report are Chen, Ya-Ling and Huang, Ming-Hung.

KPMG

Taipei, Taiwan (Republic of China) May 10, 2024

Notes to Readers

The accompanying consolidated financial statements are intended only to present the consolidated statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese) WIN Semiconductors Corp. and Subsidiaries

Consolidated Balance Sheets

March 31, 2024, December 31, and March 31, 2023

(Expressed in Thousands of New Taiwan Dollars)

		March 31, 202	24	December 31, 2	2023	_		March 31, 2024		31, 2024 December 31, 2023		March 31, 202	23		
	Assets	Amount	<u>%</u>	Amount	<u>%</u>	Amount	<u>%</u>		Liabilities and Equity	Amount	%	Amount	<u>%</u>	Amount	<u>%</u>
1100	Current assets:	# 5.500 016	0	10 225 500		10.406.165			Current liabilities:						
1100	Cash and cash equivalents (Note 6(a))	\$ 5,592,016	9	10,325,709	15	10,406,167	15	2100	Short-term borrowings (Notes 6(n), 6(ad) and 8)	\$ 5,651	-	21,129	-	15,957	-
1110	Current financial assets at fair value through profit or loss (Note 6(b))	142,395	-	143,327	-	121,756	-	2120	Current financial liabilities at fair value through profit or loss (Notes 6(b) and 6(p))	-	-	231,774	-	306,682	1
1136	Current financial assets at amortized cost (Note 6(b))	135,930	-	-	-	-	-	2130	Current contract liabilities (Note 6(x))	497,636	1	563,765	1	309,002	1
1170	Notes and accounts receivable, net (Notes 6(c) and							2170	Notes and accounts payable	1,543,946	2	1,362,255	2	724,935	1
	6(x))	1,187,921	2	1,148,666	2	777,521	1	2200	Other payables (Note $6(y)$)	2,184,497	4	2,483,014	4	3,010,200	4
1310	Inventories (Note 6(e))	5,314,115	8	5,111,206	8	5,297,351	8	2280	Current lease liabilities (Notes 6(q) and 6(ad))	104,587	-	103,105	-	108,544	-
1400	Current biological assets (Note 6(f))	52,468	-	147,945	-	162,331	-	2321	Bonds payable, current portion (Notes 6(p) and						
1470	Other current assets (Notes 6(d) and 6(m))	272,144	_1	286,474		254,295	1		6(ad))	-	-	4,743,834	7	10,568,792	15
	Total current assets	12,696,989	<u>20</u>	17,163,327	<u>25</u>	17,019,421	<u>25</u>	2322	Long-term borrowings, current portion (Notes 6(o),						
	Non-current assets:								6(ad) and 8)	4,600,680	7	2,996,728	4	2,473,067	
1510	Non-current financial assets at fair value through							2399	Other current liabilities	211,357		218,030		220,451	
	profit or loss (Note 6(b))	1,836,406	3	1,844,595	3	1,872,783	3		Total current liabilities	9,148,354	14	12,723,634	18	17,737,630	<u>26</u>
1517	Non-current financial assets at fair value through other comprehensive income (Note 6(b))	4,197,845	6	3,652,534	5	2,196,107	3		Non-current liabilities:						
1550		, ,	0	3,032,334	3	2,190,107	3	2540	Long-term borrowings (Notes 6(o), 6(ad) and 8)	17,943,041	28	20,029,576	30	16,168,030	24
1550	Investments accounted for using equity method (Note $6(g)$)	10,773,043	17	10,564,024	15	10,906,111	16	2570	Deferred tax liabilities	4,164	-	-	-	4,320	-
1600	Property, plant and equipment (Notes 6(i) and 8)	30,643,992		31,312,139	45	31,662,171		2580	Non-current lease liabilities (Notes 6(q) and 6(ad))	866,990	1	854,968	1	904,742	1
1755	Right-of-use assets (Note 6(j))	1,018,662		1,015,126	1	1,075,205	1	2600	Other non-current liabilities (Notes 6(s), 6(ad) and	193,033		210,526		211,282	
1760	Investment property (Note 6(k))	1,041,986	2	1,043,315	1	1,047,303	1		7)	40.00	• •			400	
1780	Intangible assets (Note 6(1))	522,580	1	527,488	1	557,560	1		Total non-current liabilities	19,007,228	<u>29</u>	21,095,070	31	17,288,374	
1830	Non-current biological assets (Note 6(f))	92,059	_	107,330	_	235,816	_		Total liabilities	28,155,582	43	33,818,704	49	35,026,004	_51
1840	Deferred tax assets	1,206,721	2	1,129,073	2	821,615	1		Equity (Notes 6(b), 6(g), 6(h), 6(p), 6(u) and 6(v)):						
1915	Prepayments for business facilities	291,593		382,096	1	1,160,742	2	3110	Ordinary shares	4,239,404	7	4,239,404	6	4,239,404	
1913	Other non-current assets (Notes 6(m) and 8)	423,235		426,988	1	559,800		3200	Capital surplus	9,967,931	15	9,967,188	14	9,965,055	14
1990					75			3300	Retained earnings	17,618,442	27	17,212,996	25	16,889,749	24
	Total non-current assets	52,048,122	80	52,004,708	<u>75</u>	52,095,213	<u>75</u>	3400	Other equity interests	3,478,420	6	2,535,609	4	1,194,221	2
									Total equity attributable to owners of parent	35,304,197	55	33,955,197	49	32,288,429	46
								36XX	Non-controlling interests	1,285,332	2	1,394,134	2	1,800,201	3
									Total equity	36,589,529	57	35,349,331	51	34,088,630	49
	Total assets	\$ <u>64,745,111</u>	<u>100</u>	69,168,035	<u>100</u>	69,114,634	<u>100</u>		Total liabilities and equity	\$ <u>64,745,111</u>	<u>100</u>	69,168,035	<u>100</u>	69,114,634	<u>100</u>

(English Translation of Consolidated Financial Statements Originally Issued in Chinese) WIN Semiconductors Corp. and Subsidiaries

Consolidated Statement of Comprehensive Income

For the three months ended March 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars, Except for Earnings Per Common Share)

		For the three	months	ended March 3	31
		Amount	%	Amount	%
4000	Operating revenue (Notes $6(b)$, $6(g)$ and $6(x)$)	\$ 4,442,401	100	2,859,558	100
5000	Operating costs (Notes 6(e), 6(f), 6(g), 6(i), 6(q), 6(s), 6(v), 6(y), 7 and 12)	(3,447,733)	<u>(78</u>)	(2,533,460)	<u>(88</u>)
	Gross profit from operating	994,668	22	326,098	12
	Operating expenses (Notes $6(c)$, $6(i)$, $6(q)$, $6(s)$, $6(v)$, $6(y)$, 7 and 12):				
6100	Selling expenses	(107,022)	(2)	(103,845)	(4)
6200	Administrative expenses	(292,835)	(7)	(311,968)	(11)
6300	Research and development expenses	(411,262)	(9)	(504,116)	(18)
6450	Gains (losses) on expected credit impairment	16		(922)	
	Total operating expenses	(811,103)	(18)	(920,851)	(33)
	Net operating income (loss)	183,565	4	(594,753)	(21)
	Non-operating income and expenses (Notes 6(b), 6(g), 6(i), 6(p), 6(q), 6(z), 6(ad) and 7):				
7100	Interest income	29,525	1	53,944	2
7010	Other income	17,320	-	17,262	1
7020	Other gains and losses	281,954	6	122,445	4
7050	Finance costs	(199,819)	(4)	(138,580)	(5)
7060	Share of profit of associates and joint ventures accounted for using equity method, net	(3,825)	-	(15,939)	(1)
	Total non-operating income and expenses	125,155	3	39,132	1
7900	Profit (loss) before tax	308,720	7	(555,621)	(20)
7950	Tax benefit (expense) (Note 6(t))	(41,757)	(1)	76,998	3
	Profit (loss)	266,963	6	(478,623)	
8300	Other comprehensive income:			(170,025)	<u>(17</u>)
8310	Components of other comprehensive income that will not be reclassified to profit or loss (Notes 6(g) and 6(u))				
8316	Unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive				
0310	income	573,289	13	354,727	13
8320	Share of other comprehensive income of associates and joint ventures accounted for using equity method that will not be reclassified to profit or loss	(2,011)	_	_	_
8349	Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	-	-	-	_
	Total components of other comprehensive income (loss) that will not be reclassified to profit or loss	571,278	13	354,727	13
8360	Components of other comprehensive income that will be reclassified to profit or loss (Notes 6(g) and 6(u))				
8361	Exchange differences on translation of foreign financial statements	198,094	4	40,797	1
8370	Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be	,		,	
	reclassified to profit or loss	200,948	5	35,555	1
8399	Income tax related to components of other comprehensive income that will be reclassified to profit or loss			-	
	Total components of other comprehensive income (loss) that will be reclassified to profit or loss	399,042	9	76,352	2
8300	Other comprehensive income, net	970,320	22	431,079	15
8500	Total comprehensive income	\$ 1,237,283	<u>28</u>	(47,544)	<u>(2</u>)
	Profit (loss) attributable to:				
8610	Profit (loss) attributable to owners of parent	\$ 406,726	9	(401,811)	(14)
8620	Loss attributable to non-controlling interests	(139,763)	(3)	(76,812)	(3)
		\$ 266,963	6	(478,623)	<u>(17</u>)
	Comprehensive income (loss) attributable to:			i	
8710	Comprehensive income, attributable to owners of parent	\$ 1,348,257	30	18,777	_
8720	Comprehensive loss, attributable to non-controlling interests	(110,974)	<u>(2)</u>	(66,321)	<u>(2)</u>
		\$ 1,237,283	28	(47,544)	<u>(2)</u>
	Earnings per common share (expressed in New Taiwan dollars) (Note 6(w))	,,			<u> </u>
9750	Basic earnings per share	\$0.96		(0.95)	
9850	Diluted earnings per share	\$ 0.96		(1.14)	
, 550		*		(1.11)	

(English Translation of Consolidated Financial Statements Originally Issued in Chinese) WIN Semiconductors Corp. and Subsidiaries Consolidated Statement of Changes in Equity

For the three months ended March 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars)

				Equity attri	butable to own	ners of parent					
					-	Ot	her equity intere	sts			
							Unrealized				
							gains				
				Retained earnings		Exchange	(losses) on financial assets				
				Ketaineu earnings		differences on	measured at				
						translation of	fair value		Total equity		
					Total	foreign	through other		attributable to		
	Ordinar	Capital		Unappropriated	retained	financial	comprehensive	Total other	owners of	Non-controlling	
	shares	surplus		retained earnings	earnings	statements		equity interests	parent	interests	Total equity
Balance at January 1, 2023	\$ 4,239,4	9,964,088	3,892,688	14,458,723	18,351,411	61,004	712,629	773,633	33,328,536	1,861,008	35,189,544
Appropriation and distribution of retained earnings:											
Cash dividends of ordinary shares			<u> </u>	(1,059,851)	(1,059,851)				(1,059,851		(1,059,851)
Losses for the three months ended March 31, 2023	-	-	-	(401,811)	(401,811)	-	-	-	(401,811	(76,812)	(478,623)
Other comprehensive income for the three months ended March 31, 2023						65,861	354,727	420,588	420,588	10,491	431,079
Total comprehensive income (loss) for the three months ended March 31, 2023				(401,811)	(401,811)	65,861	354,727	420,588		(66,321)	(47,544)
Changes in equity of associates accounted for using equity method	-	967	7 -	-	-	-	-	-	967	-	967
Stock option compensation cost of subsidiary										5,514	5,514
Balance at March 31, 2023	\$ 4,239,4	9,965,055	3,892,688	12,997,061	16,889,749	126,865	1,067,356	1,194,221	32,288,429	1,800,201	34,088,630
Balance at January 1, 2024	\$ 4,239,4	9,967,188	4,070,984	13,142,012	17,212,996	(12,053)	2,547,662	2,535,609	33,955,197	1,394,134	35,349,331
Profit (losses) for the three months ended March 31, 2024	-	-	-	406,726	406,726	-	-	-	406,726	(139,763)	266,963
Other comprehensive income for the three months ended March 31, 2024		<u> </u>				370,276	571,255	941,531	941,531	28,789	970,320
Total comprehensive income (loss) for the three months ended March 31, 2024		<u> </u>		406,726	406,726	370,276	571,255	941,531	1,348,257	(110,974)	1,237,283
Changes in equity of associates accounted for using equity method	-	743	3 -	-	-	-	-	-	743	-	743
Stock option compensation cost of subsidiary	-	-	-	-	-	-	-	-	-	2,172	2,172
Disposal of investments in equity instruments designated at fair value through											
other comprehensive income				(1,280)	(1,280)		1,280	1,280			
Balance at March 31, 2024	\$ 4,239,4	9,967,931	4,070,984	13,547,458	17,618,442	358,223	3,120,197	3,478,420	35,304,197	1,285,332	36,589,529

(English Translation of Consolidated Financial Statements Originally Issued in Chinese) WIN Semiconductors Corp. and Subsidiaries

Consolidated Statement of Cash Flows

For the three months ended March 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars)

	For the three months 2024	ended March 31 2023	
Cash flows from (used in) operating activities:			
Profit (loss) before tax	\$308,720	(555,621)	
Adjustments: Adjustments to reconcile profit (loss):			
Depreciation expense	1,169,538	1,077,185	
Amortization expense	27,369	29,444	
Losses on (reversal of) expected credit impairment	(16)	922	
Net losses (gains) on financial assets or liabilities at fair value through profit or loss	47,856	(340,267)	
Interest expense	199,819	138,580	
Interest income	(29,525)	(53,944)	
Dividend income	(19,809)	(17,293)	
Share-based payments	2,172	5,514	
Share of loss (profit) of associates and joint ventures accounted for using equity method	15,934	(3,035)	
Losses on disposal of property, plant and equipment	-	22,826	
Changes in biological assets at fair value	44,469	14,520	
Unrealized foreign exchange losses (gains)	149,564	(83,446)	
Gains on repurchases of bonds payable	(252,929)	(15,316)	
Gains on financial liabilities at amortised cost	(253,828) 1,353,543	775,690	
Total adjustments to reconcile profit (loss) Changes in operating assets and liabilities:	1,333,343	//3,090	
Changes in operating assets:			
Decrease in financial assets at fair value through profit or loss	_	14,500	
(Increase) decrease in notes and accounts receivable	(39,240)	138,176	
(Increase) decrease in inventories	(202,980)	122,903	
Decrease (increase) in biological assets	58,813	(72,197)	
Decrease in other current assets	27,114	23,676	
Total changes in operating assets	(156,293)	227,058	
Changes in operating liabilities:			
(Decrease) increase in contract liabilities	(66,129)	73,693	
Increase (decrease) in notes and accounts payable	181,691	(291,781)	
Decrease in other payables	(215,073)	(657,474)	
(Decrease) increase in other current liabilities	(6,673)	6,475	
(Decrease) increase in other non-current liabilities	(16,862)	523	
Total changes in operating liabilities	(123,046)	(868,564)	
Total changes in operating assets and liabilities	(279,339)	(641,506)	
Cash flows (used in) generated from operations	1,382,924	(421,437)	
Dividends received	- (64.525)	10,543	
Income taxes paid	(64,535)	(30,539)	
Net cash flows from (used in) operating activities Cash flows from (used in) investing activities:	1,318,389	(441,433)	
Proceeds from disposal of financial assets at fair value through other comprehensive income	30,300		
Acquisition of financial assets at amortized cost	(135,930)	_	
Acquisition of financial assets at fair value through profit or loss	(26,345)	(15,490)	
Proceeds from capital reduction of financial assets at fair value through profit or loss	8,116	2,208	
Acquisition of investments accounted for using equity method	-	(14,498)	
Acquisition of property, plant and equipment	(260,411)	(489,317)	
Proceeds from disposal of property, plant and equipment	-	209	
Acquisition of intangible assets	(16,190)	(34,349)	
Decrease (increase) in other non-current assets	3,753	(73,471)	
Increase in prepayments for business facilities	(42,438)	(46,966)	
Interest received	29,294	49,211	
Dividends received	7,331	6,750	
Net cash flows used in investing activities	(402,520)	(615,713)	
Cash flows from (used in) financing activities:			
Increase in short-term loans	5,651	15,957	
Decrease in short-term loans	(21,129)	-	
Proceeds from long-term debt	558,210	1,679,764	
Repayments of long-term debt	(1,391,097)	(590,000)	
Repayments of lease liabilities (Degrees) in expage in other non gurment liabilities	(17,742)	(19,259)	
(Decrease) increase in other non-current liabilities	(631)	(12.248)	
Interest paid Redemption of hands payable	(175,988)	(13,248)	
Redemption of bonds payable Net cash flows (used in) from financing activities	(4,724,694) (5,767,420)	1,073,262	
Effect of exchange rate changes on cash and cash equivalents	117,858	10,339	
Net (decrease) increase in cash and cash equivalents	$\frac{117,838}{(4,733,693)}$	26,455	
Cash and cash equivalents at beginning of period	10,325,709	10,379,712	
Cash and cash equivalents at end of period	\$	10,406,167	

(English Translation of Consolidated Financial Statements Originally Issued in Chinese) WIN Semiconductors Corp. and Subsidiaries

Notes to the Consolidated Financial Statements

March 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(1) Company history:

WIN Semiconductors Corp. (the "Company") was incorporated on October 16, 1999 as a company limited by shares and registered under the Ministry of Economic Affairs, R.O.C. The address of the Company's registered office is No. 69, Keji 7th Rd., Hwaya Technology Park, Guishan Dist., Taoyuan City, Taiwan.

The main operations of the Company and its subsidiaries (together referred to as "the Group") are as follows:

- (a) Researching, developing, manufacturing, and selling of GaAs wafers.
- (b) Developing hog farming technology and trading.
- (c) Researching, manufacturing and selling of high-density gene chips, biochip optical readers, microelectrophoresis analyzers and diagnostic tool for endometrial cancer.

(2) Approval date and procedures of the consolidated financial statements:

These consolidated financial statements was authorized for issue by the Board of Directors as of May 10, 2024.

(3) New standards, amendments and interpretations adopted:

(a) The impact of the IFRS Accounting Standards endorsed by the Financial Supervisory Commission, R.O.C. which have already been adopted.

The Group has initially adopted the following new amendments, which do not have a significant impact on its consolidated financial statements, from January 1, 2024:

- Amendments to IAS 1 "Classification of Liabilities as Current or Non-current"
- Amendments to IAS 1 "Non-current Liabilities with Covenants"
- Amendments to IAS 7 and IFRS 7 "Supplier Finance Arrangements"
- Amendments to IFRS 16 "Lease Liability in a Sale and Leaseback"

(b) The impact of IFRS issued by IASB but not yet endorsed by the FSC

The following new and amended standards, which may be relevant to the Group, have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

Standards or Interpretations

IFRS 18 "Presentation and Disclosure in Financial Statements"

Content of amendment

The standard introduces three categories of income and expenses, two income statement subtotals and one single management performance note on amendments. measures. The three combined with enhanced guidance on how to disaggregate information, set the stage for better and more consistent information for users, and will affect all the entities.

- A more structured income statement: under current standards, companies use different formats to present their results, making it difficult for investors to compare financial performance across companies. The new standard promotes a more structured income statement, introducing a newly defined 'operating profit' subtotal and a requirement for all income and expenses to be allocated between three new distinct categories based on a company's main business activities.
- Management performance measures (MPMs): the new standard introduces a definition for management performance measures, and requires companies to explain in a single note to the financial statements why the measure provides useful information, how it is calculated and reconcile it to an amount determined under IFRS Accounting Standards.
- Greater disaggregation of information: the new standard includes enhanced guidance on how companies group information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes.

Effective date per IASB

January 1, 2027

The Group is evaluating the impact on its consolidated financial position and consolidated financial performance upon the initial adoption of the abovementioned standards or interpretations. The results thereof will be disclosed when the Group completes its evaluation.

The Group does not expect the following other new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its consolidated financial statements:

- Amendments to IFRS 10 and IAS 28 "Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture"
- IFRS 17 "Insurance Contracts" and amendments to IFRS 17 "Insurance Contracts"
- Amendments to IFRS 17 "Initial Application of IFRS 17 and IFRS 9 Comparative Information"
- Amendments to IAS21 "Lack of Exchangeability"

(4) Summary of material accounting policies:

Except the following accounting policies mentioned below, the material accounting policies adopted in the consolidated financial statements are the same as those in the consolidated financial statement for the year ended December 31, 2023. For the related information, please refer to Note 4 of the consolidated financial statements for the year ended December 31, 2023.

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with the preparation and guidelines of IAS 34 "Interim Financial Reporting" which are endorsed and issued into effect by FSC, and do not include all of the information required by the Regulations and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed by the FSC (hereinafter referred to IFRS Accounting Standards endorsed by the FSC) for a complete set of the annual consolidated financial statements.

(b) Basis of consolidation

(i) List of subsidiaries in the consolidated financial statements:

				Shareholding		
			March 31,	December 31,	March 31,	
Name of investor	Name of subsidiary	Principal activity	2024	2023	2023	Remark
The Company	WIN SEMI. USA, INC.	Marketing	100.00 %	100.00 %	100.00 %	
The Company	Win Semiconductors Cayman Islands Co., Ltd. (abbrev. Win Cayman)	Investment activities	100.00 %	100.00 %	100.00 %	
The Company	WIN Venture Capital Corp. (abbrev. WVC)	Investment activities	100.00 %	100.00 %	100.00 %	
The Company	Phalanx Biotech Group, Inc. (abbrev. PBL)	Researching, manufacturing and selling of high-density gene chips and testing service	73.67 %	73.67 %	73.67 %	
The Company	WIN Earn Investment Corp.	Investment activities	100.00 %	100.00 %	100.00 %	
The Company	WIN Chance Investment Corp.	Investment activities	100.00 %	100.00 %	100.00 %	
WVC	Phalanx Biotech Group, Inc.	Researching, manufacturing and selling of high-density gene chips and testing service	1.54 %	1.54 %	1.54 %	
Win Cayman	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. (abbrev. Chainwin Cayman)	Investment activities	81.23 %	81.23 %	81.23 %	

				Shareholding		
			March 31,	December 31,	March 31,	
Name of investor	Name of subsidiary	Principal activity	2024	2023	2023	Remark
Chainwin Cayman	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Developing hog farming technology and trading	97.70 %	100.00 %	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Win Chance Agriculture Development Co., Ltd. (abbrev. Jiangsu Win Chance)	Developing hog farming technology and trading	-	-	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd. (abbrev. Jiangsu Chainwin)	Farm feed development and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Yield Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Win Lux Biotech (Cayman Islands) Co., Ltd.	Investment activities	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Shine Agriculture Development Co., Ltd.	Logistics management service	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	i-Chainwin Technology Co., Ltd.	Information software services	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Win Lux Biotech Co., Ltd.	Biotechnology service and pharmaceutical testing	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Sunlight Agriculture Development Co., Ltd. (abbrev. Jiangsu Win Sunlight)	Developing hog farming technology and trading	-	-	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Win Fortune Agriculture Development Co., Ltd.	Developing hog farming technology and trading	-	-	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Win Advane Bio-Assay Co., Ltd.	Biotechnology testing service	-	-	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Win Lux Biotech Co., Ltd.	Biotech research and development and bioassay	100.00 %	100.00 %	100.00 %	
Jiangsu Win Chance	Jiangsu Win Wonder Agriculture Development Co., Ltd.	Developing farming technology and trading	100.00 %	100.00 %	100.00 %	
Jiangsu Win Chance	Jiangsu Merit Runfu Agriculture Development Co., Ltd.	Developing hog farming technology and trading	-	100.00 %	100.00 %	(Note 2)
Jiangsu Chainwin	Jiangsu Win Boutique Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Jiangsu Chainwin	Jiangsu Win Honor Management Technology Co., Ltd.	Logistics management service	100.00 %	100.00 %	100.00 %	
Jiangsu Chainwin	Chainwin (Huaian) AloT Co., Ltd.	Information software services	100.00 %	100.00 %	100.00 %	
Jiangsu Chainwin	Jiangsu Win Sunlight Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	-	(Note 1)
Jiangsu Chainwin	Jiangsu Win Chance Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	-	(Note 1)
Jiangsu Chainwin	Jiangsu Win Fortune Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	-	(Note 1)
Jiangsu Chainwin	Jiangsu Win Advane Bio-Assay Co., Ltd.	Biotechnology testing service	100.00 %	100.00 %	-	(Note 1)
Jiangsu Win Sunlight	Jiangsu Chainwin Kang Yuan Agriculture Development Co., Ltd.	Developing hog farming technology and trading	2.30 %	-	-	(Note 1)
PBL	PhalanxBio, Inc.	Selling of high-density gene chips and testing service	100.00 %	100.00 %	100.00 %	
PBL	Phalanx Biotech Limited. (abbrev. PBL (HK))	Investment activities	100.00 %	100.00 %	100.00 %	
PBL	Guzip Biomarkers Corporation	Developing and selling of diagnostic tool for endometrial cancer	100.00 %	100.00 %	100.00 %	
PBL (HK)	Onearray Biotech (Kunshan) Co., Ltd.	Selling of high-density gene chips and testing service	100.00 %	100.00 %	100.00 %	

Note 1: Changes in organizational structure.

(ii) List of subsidiaries which are not included in the consolidated financial statements: None.

Note 2: The liquidation process is completed in $1^{\rm st}$ quarter of 2024.

Note 3: The aforementioned subsidiaries were recognized based on the reviewed financial statements by the certified public accountant.

(c) Employee benefits

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-time events.

(d) Income taxes

The income tax expenses have been evaluated and disclosed in accordance with paragraph B12 of IAS 34 "Interim Financial Reporting."

Income tax expenses for the period are best estimated by multiplying pre-tax income for the interim reporting period by the effective annual tax rate as forecasted by the management. This should be recognized fully as tax expense for the current period.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty:

The preparation of the consolidated financial statements in conformity with the Regulations and IFRS Accounting Standards (in accordance with IAS 34 "Interim Financial Reporting" and endorsed by the FSC) requires management to make judgments, estimates and assumptions that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Significant accounting estimates and assumptions made by the management may differ from the actual results and are continually evaluated and adjusted based on historical experience and other factors. The Group has considered the economic implications of climate change on critical accounting estimates and will continue evaluating the impact on its financial position and financial performance.

The preparation of the consolidated financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the consolidated financial statements for the year ended December 31, 2023. For the related information, please refer to Note 5 of the consolidated financial statements for the year ended December 31, 2023.

- (a) Judgment of whether the Group has significant influence on its investee. Please refer to Note 6(b).
- (b) Judgment of whether the Group has substantive control over its investee. Please refer to Note 6(g).

(6) Explanation of significant accounts:

Except for the following disclosure, the significant account disclosure in the consolidated financial statements for the three months ended March 31, 2024, which compare with the consolidated financial statements for the year ended December 31, 2023, was not changed significantly. For the related information, please refer to Note 6 of the consolidated financial statements for the year ended December 31, 2023.

(a) Cash and cash equivalents

	N	Iarch 31, 2024	December 31, 2023	March 31, 2023
Cash on hand	\$	251	261	230
Cash in bank		5,329,765	9,818,732	7,053,986
Time deposits		262,000	506,716	3,351,951
	\$	5,592,016	10,325,709	10,406,167

Please refer to Note 6(aa) for the currency risk and sensitivity analysis of the financial assets and liabilities of the Group.

(b) Financial instruments

(i) Financial assets and liabilities at fair value through profit or loss:

		March 31, 2024	December 31, 2023	March 31, 2023
Mandatorily measured at financial assets at fair value through profit or loss:				
Non-derivative financial assets				
Publicly traded stocks (Note 1)	\$	439,989	516,759	482,729
Money market funds		137,527	137,088	111,617
Private fund (Note 1)(Note 2)	_	1,401,285	1,334,075	1,400,193
Total	\$ _	1,978,801	1,987,922	1,994,539
Current	\$	142,395	143,327	121,756
Non-current	_	1,836,406	1,844,595	1,872,783
	\$	1,978,801	1,987,922	1,994,539

Note 1: As of March 31, 2024, December 31 and March 31, 2023, part of the private fund and publicly traded stocks were during the lock-up period.

Note 2: The 32.88% shares of the Group in NFC Fund II L.P. is deemed as mutual fund. Since the Group is only a limited partner of the fund, it cannot be allowed any representative to take part in the decision making of the policy of NFC Fund II L.P. As a result, the Group has no significant influence over the company.

	M	larch 31, 2024	December 31, 2023	March 31, 2023
Mandatorily measured at current financial liabilities at fair value through profit or loss				
Convertible bonds with embedded derivatives	\$	-	231,774	306,682

The derivative financial instruments arose from the issuance of overseas convertible bonds of the Group disclosed in Note 6(p).

Refer to Note 6(z) for the amount of re-measurement at fair value recognized in profit or loss.

(ii) Current financial assets at amortized cost

	N	March 31, 2024	December 31, 2023	March 31, 2023
Time deposits over three months	\$	135,930		

The Group has assessed that these financial assets are held to maturity to collect contract cash flows, which consist solely of payments of principal and interest on principal amount outstanding. Therefore, these investments were classified as financial assets measured at amortized cost.

(iii) Non-current financial assets at fair value through other comprehensive income (FVOCI):

	March 31,		December 31,	March 31,
		2024	2023	2023
Stocks listed on domestic markets	\$	647,691	707,122	82,524
Stocks listed on US markets		3,180,984	2,571,003	1,465,117
Non-public stocks		369,170	374,409	648,466
	\$	4,197,845	3,652,534	2,196,107

The Group decided to hold these equity instruments, which are not held for trading, at fair value through other comprehensive income.

For the three months ended March 31, 2024 and 2023, the Group received dividend income \$14,329 thousand and \$12,236 thousand, respectively, of the equity investment designated at fair value though other comprehensive income.

For the three months ended March 31, 2024, the Group disposed its equity investments designated at fair value through other comprehensive income, which is currently acquired by other, at a fair value of \$30,300 thousand, resulting in the loss on disposal, accumulated in other equity of \$1,280 thousand to be reclassified from other equity to retained earnings upon derecognition.

For the three months ended March 31, 2023, there were no disposals of equity investments at fair value through other comprehensive income, and the gains and losses accumulated in other equity were not transferred to retained earnings during the period.

(iv) Sensitivity analysis in the equity price risk:

If the equity price changes, the impact to comprehensive income, using the sensitivity analysis based on the same variables except for the price index for both periods, will be as follows:

	For the three months ended March 31, 2024				onths ended , 2023
Prices of securities at the reporting date		After-tax other comprehensive income	After-tax profit (loss)	After-tax other comprehensive income	After-tax profit (loss)
Increasing 3%	\$_	125,935	13,200	65,883	14,482
Decreasing 3%	\$_	(125,935)	(13,200)	(65,883)	(14,482)

(v) As of March 31, 2024, December 31 and March 31, 2023, the financial assets were not pledged. For information on the Group's credit risk, currency risk, and fair value information was disclosed in Note 6(aa).

(c) Notes and accounts receivable, net

	N	1arch 31, 2024	December 31, 2023	March 31, 2023	
Notes receivable	\$	1,544	1,351	839	
Accounts receivable		1,186,437	1,148,140	778,610	
Less: loss allowance		(60)	(825)	(1,928)	
	\$	1,187,921	1,148,666	777,521	

The Group applies the simplified approach to provide for its loss allowance used for expected credit losses, which permit the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, notes and accounts receivable have been grouped based on shared credit risk characteristics and days past due, as well as incorporate forward looking information.

The loss allowance provision was determined as follows:

(i) The segment of foundry and agriculture technology:

			March 31, 2024	
			Weighted-	Lifetime
	Gross carrying amount		average expected loss rate	expected credit loss allowance
Not past due	\$ 1,145,507		0%	-
Past due 1~60 days		34,271	0%	-
Past due 61~120 days		349	0%	-
Past due 121~180 days		-	8.82%~23.75%	-
Past due more than 181 days			100%	
	\$	1,180,127		
]	December 31, 2023	
			Weighted-	Lifetime
	Gı	ross carrying amount	average expected loss rate	expected credit loss allowance
Not past due	\$	1,079,886	0%	-
Past due 1~60 days		61,409	0%	-
Past due 61~120 days		1,125	0%	-
Past due 121~180 days		-	8.82%~23.75%	-
Past due more than 181 days			100%	
	\$	1,142,420		
			March 31, 2023	
			Weighted-	Lifetime
	Gi	ross carrying amount	average expected loss rate	expected credit loss allowance
Not past due	\$	734,368	0%	-
Past due 1~60 days		35,600	0%	-
Past due 61~120 days		2,436	0%	-
Past due 121~180 days		-	1.02%~4.35%	-
Past due more than 181 days		1,155	100%	1,155
	\$	773,559		1,155

(ii) The segment of gene chip testing service:

			March 31, 2024		
			Weighted-	Lifetime	
	Gross carrying amount 6,076		average expected	expected credit	
Not most due			loss rate 0%~2.64%	loss allowance	
Not past due	Þ	6,076		-	
Past due 1~60 days		1,206	0%~4.80%	-	
Past due 61~120 days		508	0%~7.24%	33	
Past due 121~180 days		42	0%~38.89%	5	
Past due more than 181 days		22	100%	22	
	\$	7,854		<u>60</u>	
]	December 31, 2023		
	~		Weighted-	Lifetime	
	Gı	ross carrying amount	average expected loss rate	expected credit loss allowance	
Not past due	\$	4,407	0%~2.64%		
Past due 1~60 days		1,821	0%~4.80%	13	
Past due 61~120 days		31	0%~7.24%	-	
Past due 121~180 days		-	0%~38.89%	-	
Past due more than 181 days		812	100%	812	
•	\$	7,071		825	
			March 31, 2023		
			Weighted-	Lifetime	
	Gı	ross carrying	average expected	expected credit	
NT 1	<u></u>	amount	loss rate	loss allowance	
Not past due	\$	3,972	0%~2.64%	1	
Past due 1~60 days		988	0%~7.57%	6	
Past due 61~120 days		176	0%~15.58%	15	
Past due 121~180 days		4	0%~44.44%	1	
Past due more than 181 days		750	100%	750	
	\$	5,890		<u>773</u>	

The movements of loss allowance were as follows:

	For the t months e March 31	nded	For the three months ended March 31, 2023
Beginning balance	\$	825	985
Impairment losses recognized (gains on reversal of impairment)		(16)	922
Amounts written off		(750)	-
Effect of changes in foreign exchange rates		1	21
Ending balance	\$	60	1,928

As of March 31, 2024, December 31 and March 31, 2023, the notes and accounts receivable were not discounted nor pledged.

(d) Other receivables (recognized as other current assets)

		March 31, 2024	December 31, 2023	March 31, 2023
Other receivables	\$	31,431	19,999	42,076
Less: loss allowance	_	_		
	\$_	31,431	19,999	42,076

As of March 31, 2024, December 31 and March 31, 2023, other receivables were not past due nor impaired.

The information on the Group's credit risk was disclosed in Note 6(aa).

(e) Inventories

		March 31, 2024	December 31, 2023	March 31, 2023
Raw materials, supplies and spare parts	\$	3,770,782	3,697,213	4,177,392
Work in process		972,958	1,062,116	657,805
Finished goods	_	570,375	351,877	462,154
	\$_	5,314,115	5,111,206	5,297,351

Except for cost of goods sold and inventories recognized as expenses, the remaining gains or losses which were recognized as operating cost or deduction of operating cost were as follows:

	For the three months ended			
	Mar	ch 31, 2024	March 31, 2023	
Losses on valuation of inventories and obsolescence	\$	39,683	110,018	
Unallocated overheads	\$	160,042	17,531	
Revenue from sale of scraps	\$	(6,924)	(6,758)	
Losses on physical inventory count	\$	44	2,076	

As of March 31, 2024, December 31 and March 31, 2023, the inventories were not pledged.

(f) Biological assets

(i) List of biological assets:

	Ma	arch 31,	December 31,	March 31,
		2024	2023	2023
Consumable biological assets	\$	52,468	147,945	162,331
Bearer biological assets	\$	92,059	107,330	235,816

(ii) Movements in biological assets:

	mor	the three oths ended ch 31, 2024	For the three months ended March 31, 2023
Beginning balance	\$	255,275	366,922
Increase due to purchase		9,076	-
Input costs		191,644	218,117
Depreciation expenses		(10,879)	(28,323)
Decrease due to sales and disposals		(259,533)	(145,920)
Changes in fair value less costs to sell due to price changes		(44,469)	(14,520)
Effect of changes in foreign exchange rates		3,413	1,871
Ending balance	\$	144,527	398,147
Current	\$	52,468	162,331
Non-current		92,059	235,816
	\$	144,527	398,147

For the three months ended March 31, 2024 and 2023, the losses of \$44,469 thousand and \$14,520 thousand, respectively, were recognized as operating costs of the consolidated statement of comprehensive income as a result of the remeasurement of biological assets at the higher of its carrying amount or fair value less costs to sell.

(iii) The numbers of the Group's biological assets were as follows:

Unit: head

	March 31, 2024	December 31, 2023	March 31, 2023
Farrows, hogs and breeders	18,834	39,672	45,101

(iv) Fair value

There were no significant addition regarding the fair value of the Group's biological assets. For the related information, please refer to Note 6(f) of the consolidated financial statements for the year ended December 31, 2023.

(v) As of March 31, 2024, December 31 and March 31, 2023, the biological assets were not pledged.

(g) Investments accounted for using equity method

The components of investments accounted for using the equity method at the reporting date were as follows:

	March 31,	December 31,	March 31,
	2024	2023	2023
Associates	\$10,773,043	10,564,024	10,906,111

(i) Associates

Associates which are material to the Group consisted of the followings:

		Main Operating Location/ Registered	Proportion of Shareholding and Voting Rights		
Name of Associates	Main Businesses and Products	Country of the Company	March 31, 2024	December 31, 2023	March 31, 2023
Jiangsu CM/Chainwin Agriculture Development Co., Ltd. (abbrev. Jiangsu CM/Chainwin)	farming technology and	China	49 %	49 %	49 %
ITEQ Corporation (abbrev. ITEQ)	Manufactures and sells mass lamination boards, copper-clad laminates, prepreg, and electronic components	Taiwan	23.79 %	23.79 %	23.79 %

The fair value of significant associate listed on the Taiwan Stock Exchange Corporation (TWSE) which is material to the Group is as follows:

	M	larch 31,	December 31,	March 31,	
	2024		2023	2023	
ITEQ	\$	8,487,343	7,321,736	6,760,518	

The following consolidated financial information of significant associates has been adjusted according to individually prepared IFRS financial statements of these associates.

1) The consolidated financial information of Jiangsu CM/Chainwin:

	N	March 31, 2024	Dece	ember 31, 2023	March 31, 2023
Current assets	\$	141,937		134,735	285,097
Non-current assets		1,155,834		1,140,896	1,155,254
Current liabilities		(153,209))	(116,239)	(72,002)
Non-current liabilities		(29,925)	·	(29,003)	(30,068)
Net assets	\$ <u></u>	1,114,637		1,130,389	1,338,281
			mon <u>Marc</u>		For the three months ended March 31, 2023
Operating revenue			\$	84,289	229,376
Losses			\$	(36,998)	(68,700)
Other comprehensive income					
Total comprehensive loss			\$	(36,998)	(68,700)
			mon	the three ths ended ch 31, 2024	For the three months ended March 31, 2023
Carrying amount of equity of Jiangsu attributable to the Group at the beg			\$	552,336	684,221
Losses attributable to the Group				(18,129)	(33,663)
Exchange differences on translation of statements attributable to the Ground		eign financial		(13,779)	9,642
Shares of net assets of Jiangsu CM/C	hainv	vin at the end		520,428	660,200
Add: Effect of changes in foreign exc	chang	e rates		24,134	(5,984)
Carrying amount of equity of Jiangsu attributable to the Group at the end		Chainwin	\$	544,562	654,216

2) The consolidated financial information of ITEQ:

		March 31, 2024	Ι	December 31, 2023	March 31, 2023
Current assets	\$	21,492,904	_	21,306,421	21,478,590
Non-current assets		12,686,688		12,073,219	12,075,808
Current liabilities		(10,481,779))	(10,539,833)	(11,102,363)
Non-current liabilities		(3,820,539)) _	(3,399,959)	(3,252,067)
Net assets	\$	19,877,274	=	19,439,848	<u>19,199,968</u>
			n	For the three nonths ended larch 31, 2024	For the three months ended March 31, 2023
Operating revenue			\$	6,154,685	6,259,655
Profit			\$	153,612	73,983
Other comprehensive income			_	825,128	99,991
Total comprehensive income			\$_	978,740	173,974
			m	For the three nonths ended March 31, 2024	For the three months ended March 31, 2023
Carrying amount of equity of ITEQ Group at the beginning	attrib	outable to the	\$	9,977,473	10,143,903
Profit attributable to the Group				14,304	23,396
Comprehensive income attributable	to the	e Group		212,716	25,913
Changes in capital surplus of associa	ates		_	743	967
Carrying amount of equity of ITEQ Group at the end	attrib	outable to the		10,205,236	10,194,179
Less: Goodwill and other			_	(5,339,924)	(5,359,849)
Shares of net assets of ITEQ at the e	end		\$_	4,865,312	4,834,330

Summary of financial information for the individually insignificant investments in associates accounted for using equity method were as follows. The aforementioned financial information was included in the consolidated financial statements of the Group:

	March 31, 2024		December 31, 2023	March 31, 2023	
Total equity of the individually insignificant investments in associates	\$	23,245	34,215	57,716	

	For the three months ended March 31, 2024		For the three months ended March 31, 2023	
Attributable to the Group:				
Profit (losses)	\$	(12,109)	13,302	
Other comprehensive income				
Total comprehensive income (loss)	\$	(12,109)	13,302	

(ii) Pledge to secure

As of March 31, 2024, December 31 and March 31, 2023, the investments accounted for using equity method were not pledged.

(iii) Judgment of whether the Group has substantive control over its investee

The Group holds 49% of the outstanding voting shares of Rainbow Star Group Limited and is the single largest shareholder of the investee. The remaining 51% of Rainbow Star Group Limited's shares are concentrated within specific shareholders, and therefore the Group cannot obtain more than half of the total number of Rainbow Star Group Limited directors, and it also cannot obtain more than half of the voting rights at a shareholders' meeting. As a result, it is determined that the Group has significant influence but not control over Rainbow Star Group Limited.

The Group holds 23.79% of the outstanding voting shares of ITEQ Corporation (hereinafter referred to as "ITEQ") and is the single largest shareholder of the investee. Although the remaining 76.21% of ITEQ's shares are not concentrated within specific shareholders, the Group still cannot obtain more than half of the total number of ITEQ directors, and it also cannot obtain more than half of the voting rights at a shareholders' meeting. As a result, it is determined that the Group has significant influence but not control over ITEQ.

(h) Material non-controlling interests of subsidiaries

The material non-controlling interests of subsidiaries were as follows:

			Percentage of non-controlling interests				
	Subsidiaries	Registration	March 31, 2024	December 31, 2023	March 31, 2023		
_	Substatites	Registi ation	2027	2023	2023		
	Chainwin Cayman	Cayman Islands	18.77 %	18.77 %	18.77 %		

The following information of the aforementioned subsidiaries have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers. Included in the information are the fair value adjustment made during the acquisition and relevant difference in accounting principles between the Group as at the acquisition date. Intergroup transactions were not eliminated in this information.

		March 31, 2024	December 31, 2023	March 31, 2023
Current assets	\$	2,589,562	2,857,317	3,853,385
Non-current assets		12,577,548	12,529,682	13,691,154
Current liabilities		(249,915)	(277,307)	(449,392)
Non-current liabilities	_	(8,703,457)	(8,348,181	(8,267,608)
Net assets	\$_	6,213,738	6,761,511	8,827,539
Non-controlling interests	\$_	1,166,544	1,269,380	1,657,249
			For the three months ended March 31, 2024	For the three months ended March 31, 2023
Operating revenue			\$ 104,358	
Losses			\$ (700,900	(351,556)
Other comprehensive income			153,127	55,871
Total comprehensive loss			\$(547,773	(295,685)
Losses attributable to non-controlling interests			\$ <u>(131,584</u>	(66,000)
Comprehensive loss, attributable to non-controlling interests			\$8	(55,511)
			For the three months ended March 31, 2024	For the three months ended March 31, 2023
Net cash flows used in operating activities			\$ (101,929	
Net cash flows used in investing activities			(149,213	(159,808)
Net cash flows from financing activities			(189,649	1,014,147
Effect of changes in foreign exchange rate			160,416	(45,954)
(Decrease) increase in cash and cash equivalent	ts		\$(280,375	694,567

(i) Property, plant and equipment

The movements in property, plant and equipment were as follows:

		Land	Buildings and structures	Machinery and equipment	Factory and equipment	Other equipment	Construction in progress and inspection- awaited devices	Total
Cost:	_	Land	structures	equipment	equipment	equipment	awaited devices	Total
Balance as of January 1, 2024	\$	3,761,153	11,358,474	17,643,557	8,215,687	493,129	5,515,934	46,987,934
Additions		-	-	30,683	43,031	2,261	58,853	134,828
Reclassification (Note)		-	-	118,105	54,403	361	(56,005)	116,864
Disposals		-	-	(208,583)	(24,301)	(6,101)	-	(238,985)
Effect of changes in foreign exchange rate	s _	-	158,646	7,621	20,038	2,495	42,489	231,289
Balance as of March 31, 2024	\$_	3,761,153	11,517,120	17,591,383	8,308,858	492,145	5,561,271	47,231,930
Balance as of January 1, 2023	\$	2,546,534	9,478,472	17,648,311	6,689,192	668,701	9,406,592	46,437,802
Additions		-	2,885	141,136	13,777	8,193	279,506	445,497
Reclassification (Note)		-	1,582,325	2,018,450	143,876	14,902	(3,108,593)	650,960
Disposals		-	(15,076)	(1,152,041)	(500,600)	(96,267)	-	(1,763,984)
Effect of changes in foreign exchange rate	es _	-	51,718	590	3,519	554	8,066	64,447
Balance as of March 31, 2023	\$_	2,546,534	11,100,324	18,656,446	6,349,764	596,083	6,585,571	45,834,722
Accumulated depreciation and impairment losses:	_							
Balance as of January 1, 2024	\$	-	1,717,763	10,638,635	2,964,965	236,515	117,917	15,675,795
Depreciation		-	139,143	749,221	215,129	27,716	-	1,131,209
Disposals		-	-	(208,583)	(24,301)	(6,101)	-	(238,985)
Effect of changes in foreign exchange rate	s _	-	11,562	418	(1,760)	1,375	8,324	19,919
Balance as of March 31, 2024	\$_	-	1,868,468	11,179,691	3,154,033	259,505	126,241	16,587,938
Balance as of January 1, 2023	\$	-	1,193,693	10,327,673	3,073,301	297,129	-	14,891,796
Depreciation		-	121,871	699,160	157,676	42,076	-	1,020,783
Disposals		-	(15,076)	(1,151,300)	(500,600)	(73,973)	-	(1,740,949)
Effect of changes in foreign exchange rate	s _	-	583	(2)	113	227		921
Balance as of March 31, 2023	\$_	-	1,301,071	9,875,531	2,730,490	265,459	<u> </u>	14,172,551
Carrying amount:	_							
Balance as of January 1, 2024	\$	3,761,153	9,640,711	7,004,922	5,250,722	256,614	5,398,017	31,312,139
Balance as of March 31, 2024	\$	3,761,153	9,648,652	6,411,692	5,154,825	232,640	5,435,030	30,643,992
Balance as of January 1, 2023	\$	2,546,534	8,284,779	7,320,638	3,615,891	371,572	9,406,592	31,546,006
Balance as of March 31, 2023	\$	2,546,534	9,799,253	8,780,915	3,619,274	330,624	6,585,571	31,662,171

Note: Inventories and prepayments for business facilities were reclassified as property, plant and equipment.

(i) Pledge to secure

As of March 31, 2024, December 31 and March 31, 2023, the property, plant and equipment were subject to a registered debenture to secured bank loans and line of credit, the collateral for these long-term borrowings was disclosed in Note 8.

(ii) Property, plant and equipment under construction

The Group leased certain parcels pieces of land for the construction of its new factories, with the total amounts of \$5,113,948 thousand and \$5,207,421 thousand as of March 31, 2024 and 2023, respectively.

(iii) For the three months ended March 31, 2024 and 2023, capitalized interest expenses amounted to \$19,886 thousand and \$50,954 thousand, respectively. The annual interest rates at which these interest expenses were capitalized ranged from 1.50%~5.88% and 1.14%~5.76%, respectively.

(j) Right-of-use assets

	Land	Buildings and structures	Other equipment	Total
Carrying amount:				
Balance as of January 1, 2024 \$	683,460	317,860	13,805	1,015,125
Balance as of March 31, 2024 \$	694,735	311,444	12,483	1,018,662
Balance as of January 1, 2023 \$	747,948	341,753	10,028	1,099,729
Balance as of March 31, 2023	735,399	331,013	8,793	1,075,205

There were no significant additions, recognition and reversal of impairment losses of right-of-use assets for the three months ended March 31, 2024 and 2023. As of March 31, 2024, depreciation of right-of-use assets was disclosed in Note 12(a). Other information was disclosed in Note 6(j) of the consolidated financial statements for the year ended December 31, 2023.

(k) Investment property

	Land		Buildings and	
			structures	Total
Carrying amount:				
Balance as of January 1, 2024	\$	963,127	80,188	1,043,315
Balance as of March 31, 2024	\$	963,127	78,859	1,041,986
Balance as of January 1, 2023	\$	963,127	85,505	1,048,632
Balance as of March 31, 2023	\$	963,127	84,176	1,047,303
Fair value:				_
Balance as of January 1, 2024			\$	1,130,325
Balance as of March 31, 2024			<u>\$</u>	1,127,502
Balance as of March 31, 2023			\$	1,172,669

There were no significant additions, disposal, or recognition and reversal of impairment losses of investment property for the three months ended March 31, 2024 and 2023. As of March 31, 2024, depreciation of investment property was disclosed in Note 12(a). Other information was disclosed in Note 6(k) of the consolidated financial statements for the year ended December 31, 2023.

When measuring the fair value of its investment property, the Group considered the present value of net cash flows to be generated from leasing the property. The expected net cash flows were discounted using the yield to reflect its specified inherit risk on the net cash flows. The inputs to the valuation technique used for measuring fair value were categorized as a Level 2 fair value. As of March 31, 2024, December 31 and March 31, 2023, the yield applied to the net annual rentals to determine fair value of property for which current prices in an active market were unavailable, was as follows:

	March 31,	December 31,	March 31,	
Location	2024	2023	2023	_
Hsinchu	0.54%	0.83%	0.25%	-

As of March 31, 2024, December 31 and March 31, 2023, the investment properties were not pledged.

(1) Intangible assets

Complex amount	 chnical ow-how	Computer software and information systems	Goodwill	Others	Total
Carrying amount:					
Balance as of January 1, 2024	\$ 29,927	158,047	324,962	14,552	527,488
Balance as of March 31, 2024	\$ 28,714	152,365	330,308	11,193	522,580
Balance as of January 1, 2023	\$ 35,792	201,522	324,962	29	562,305
Balance as of March 31, 2023	\$ 34,355	199,298	323,885	22	557,560

There was no significant additions, disposals, or recognition and reversal of impairment losses of intangible assets for the three months ended March 31, 2024 and 2023. As of March 31, 2024, amortization of intangible assets was disclosed in Note 12(a). Other information was disclosed in Note 6(l) of the consolidated financial statements for the year ended December 31, 2023.

As of March 31, 2024, December 31 and March 31, 2023, the intangible assets were not pledged.

(m) Other current assets and other non-current assets

		March 31, 2024	December 31, 2023	March 31, 2023
Tax refund receivables	\$	59,854	65,808	52,103
Other receivables		31,431	19,999	42,076
Prepayments to suppliers		4,210	501	845
Prepaid expenses		121,261	144,837	104,459
Offset against business tax payable		44,193	43,915	43,699
Restricted assets		241,626	243,819	342,976
Refundable deposits		93,388	94,425	148,445
Long-term prepayments to suppliers		75,239	75,239	55,424
Others		24,177	24,919	24,068
	\$_	695,379	713,462	814,095
Short-term borrowings				
		March 31, 2024	December 31, 2023	March 31, 2023
Secured short-term borrowings (in RMB)	\$	5,651	21,129	15,957
Unsecured short-term borrowings	\$	-	-	
Unused bank credit lines for short-term borrowings	\$ _	1,534,349	1,649,521	1,650,793
Unused bank credit lines for short-term and				

The collateral for these short-term borrowings were disclosed in Note 8.

(o) Long-term borrowings

Annual interest rate

long-term borrowings

(n)

		March 31, 2024	December 31, 2023	March 31, 2023
Secured long-term borrowings (in TWD)	\$	1,200,000	1,200,000	-
Secured long-term syndicated borrowings (in USD)		8,433,331	8,083,027	7,983,850
Unsecured long-term borrowings (in TWD)		12,910,390	13,743,277	10,657,247
Less: Current portion	_	(4,600,680)	(2,996,728)	(2,473,067)
Total	\$ _	17,943,041	20,029,576	16,168,030
Unused bank credit lines for long-term borrowings	\$	8,758,500	9,582,867	11,643,250
Annual interest rate	_1	1.00%~5.83%	1.00%~5.84%	0.88%~5.31%
Expiry date	202	25/02/15~2038/08/14	2025/02/15~2038/08/14	2024/05/17~2029/01/20

As of March 31, 2024, the remaining balances of the borrowing due were as follows:

Redemption period	Amount
April 1, 2024~March 31, 2025	\$ 4,600,680
April 1, 2025~March 31, 2026	12,353,919
April 1, 2026~March 31, 2027	2,278,792
April 1, 2027~March 31, 2028	1,518,792
April 1, 2028 and after	1,791,538
	\$ 22,543,721

- (i) The unused bank credit lines for short-term and long-term borrowings at the reporting date were disclosed in Note 6(n).
- (ii) The collateral for these long-term borrowings were disclosed in Note 8.
- (iii) In December 2021, the Group entered into a three-year syndicated loan agreement with Far Eastern International Bank and other ten banks. The total credit facility under this loan agreement is US\$300,000 thousand.

The related financial covenants and restrictions for the syndicated loans mentioned above were as follows:

- 1) At the end of reporting period, current ratio (current assets / current liabilities): shall not lower than 100%;
- 2) Interest coverage ratio [(profit before tax + depreciation + amortization + interest expense) / interest expense)]: shall not be lower than 100%; and
- 3) Tangible net assets value (equity— intangible assets): shall not be lower than NT\$20,000,000 thousand.

After the guarantor signs the loan agreement, the aforementioned financial ratio and criteria will be reviewed semi-annually, which are based on the year-end consolidated financial statements audited by the Certified Public Accountants (CPAs) that are approved by the leading bank, as well as the semi-annual consolidated financial statements reviewed by the CPAs.

Although the Group breached the above restriction of the current ratio in the second quarter of 2023, the Group was able to obtain a waiver letter in June 2023 after negotiating with the banks. Hence, the Group need not have to repay the loans immediately.

For the year ended December 31, 2023, the Group were in compliance with the above financial covenants and restrictions.

(p) Bonds payable

The details of bonds payable were as follows:

		rch 31, 2024	December 31, 2023	l	March 31, 2023
Overseas convertible bonds issuance balance	\$	-	4,869,216		10,952,937
Less: Unamortized discounted bonds payable		-	(125,382)		(384,145)
Current portion			(4,743,834)		(10,568,792)
	\$			_	-
Proceeds from issuance (less transaction cost ar	nounte	d to \$89,22	6 thousand)	\$	13,902,774
Equity components (less transaction cost amorti	ized to	equity com	ponent of \$4,147		(639,583)
thousand)					
Embedded derivatives instruments—put/ call op	ptions				(139,920)
Liability components at the issuance date (less	transac	tion cost al	located to liability		13,123,271
component of \$85,079 thousand)					
Interest expense at an effective interest rate of 1	1.28%				419,158
Repurchases/ redeems of bonds payable					(13,542,429)
Liability components at March 31, 2024				\$	_

The Company resolved to issue the first unsecured overseas convertible bonds, as proposed in the Board of Directors meeting held on November 27, 2020, which had been approved by the Financial Supervisory Commission with approval No.1090377907 on December 25, 2020 and been issued on the Singapore Exchange Securities Trading Limited on January 14, 2021. The Company issued the 5 years unsecured convertible bond, amounting to US\$500,000 thousand without coupon rate, with the maturity dates on January 14, 2026.

Unless previously redeemed, repurchased, and cancelled or converted, regulations and except during the closed period, the bonds may be converted into the Company's common shares pursuant to the applicable laws and regulations and the indenture at any time starting from the next day immediately after three months from the issue date to (1) the 10 day prior to the maturity date or (2) the 5 business day prior to the applicable redemption date on which a bondholder exercises its put right or the applicable date (other than the maturity date) on which the Company exercises its redemption right.

The conversion price was 140% of the closing price of the Company's common shares on the Taipei Exchange on the pricing date, which was NT\$497. The number of common shares to be delivered upon conversion of any bond will be determined with the principal amount of the bonds multiplied by the fixed exchange rate, which is NT\$27.984 to US\$1, which as determined on the pricing date and divided by the conversion price in effect on the date of conversion. After the issuance of the bonds, the conversion price shall be adjusted in accordance with the relevant anti-dilution provisions of the indenture.

The above-mentioned convertible bonds included liabilities and equity components. The equity component was accounted under the capital surplus-stock option. The effective interest rate originally recognized for the liability component was 1.28%.

For the three months ended March 31, 2024, the Company had redeemed its convertible bonds, at the principal amount of USD\$161,000 thousand, due to requirements of the bondholders. On February 23, 2024, as more than 90% of the bonds had been redeemed, the Company redeemed in advanced the remaining bonds, at the principal amount of USD\$13,000 thousand, in accordance with the indenture, resulting in the gains, amounting \$253,828 thousand, to be recognized as other gains and losses. Please refer to note 6(z).

For the three month ended March 31, 2023, the Company has repurchased the first issued unsecured overseas convertible bonds in 2020 at the principle amount of US\$5,000 thousand, consequently, derecognized the related derivative financial liabilities. The difference between the repurchased amount and the carrying amount was recognized under other gains and losses, please refer to Note 6(z). There was no such transaction for the three month ended March 31, 2023.

(q) Lease liabilities

The carrying amounts of lease liabilities were as follow:

	March 31,	December 31,	March 31,
	2024	2023	2023
Current	\$ 104,587	103,105	108,544
Non-current	\$ 866,990	854,968	904,742

For the maturity analysis, please refer to Note 6(aa).

The amounts recognized in profit or loss were as follows:

	mon	the three ths ended th 31, 2024	For the three months ended March 31, 2023
Interest expenses on lease liabilities	\$	5,693	5,982
Expenses relating to short-term leases	\$	2,525	1,094
Expenses relating to leases of low-value assets, excluding short-term leases of low-value assets	\$	379	395

The amounts recognized in the statement of cash flows for the Group was as follows:

	For the three	For the three
	months ended	months ended
	March 31, 2024	March 31, 2023
Total cash outflow for leases	\$	24,358

(i) Land, buildings and structures leases

The Group leases land, buildings and structures for its plants, parking lots and staff dormitories. The leases of them typically run for a period of 3 to 50 years.

(ii) Other leases

The Group leases printer and transportation equipment, with lease terms of 2 to 10 years.

(iii) Others

Parts of the leases of transportation equipment, machinery and equipment, office and staff dormitories are with contract terms of less than one year. These leases are short-term. The Group has elected not to recognize right-of-use assets and lease liabilities for these leases. Also, some leases contain cancellation options exercisable by the Group. In which lease is not reasonably certain to use an optional extended lease term, payments associated with the optional period are not included within lease liabilities.

(r) Operating lease

There were no significant changes in operating lease for the three months ended March 31, 2024 and 2023. Please refer to Note 6(r) of the consolidated financial statements for the year ended December 31, 2023 for other related information.

(s) Employee benefits

(i) Defined benefit plans

At the end of the prior fiscal year, there was no material volatility of the market, no material reimbursement and settlement or other material one-time events. As a result, pension cost in the consolidated interim financial statements was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate as of December 31, 2023 and 2022.

The Group's expenses recognized in profit or loss were as follows:

	n	For the three nonths ended [arch 31, 2024]	For the three months ended March 31, 2023
Operating costs	\$	-	-
Operating expenses	_	552	591
	\$ _	552	591

(ii) Defined contribution plans

The Group's expenses under the pension plan cost to the Bureau of Labor Insurance for the three months ended March 31, 2024 and 2023 were as follows:

	months ended	months ended	
	March 31, 2024	March 31, 2023	
Operating costs	\$ 23,675	23,926	
Operating expenses	8,353	7,841	
	\$32,028	31,767	

(iii) The Group's mainland China subsidiaries have a defined contribution plan. Monthly contributions to an independent fund administered by the government in accordance with the pension regulations in the People's Republic of China (PRC) are based on certain percentage of employees' monthly salaries and wages. Other than the monthly contributions, the Group has no further obligations. For the three months ended March 31, 2024 and 2023, the Group recognized the pension costs in accordance with the pension regulations and amounted to \$2,473 thousand and \$4,720 thousand, respectively.

(t) Income tax

(i) The amount of income tax expense (benefit) was as follows:

	For the three	For the three
	months ended	months ended
	March 31, 2024	March 31, 2023
Income tax expense (benefit)	\$41,757	(76,998)

- (ii) There was no income tax expense recognized in other comprehensive income for the three months ended March 31, 2024 and 2023.
- (iii) Assessment

The Company's corporate income tax returns for all the years through 2022 were assessed by the tax authorities.

(u) Capital and other equity

Except for the following disclosure, there was no significant change for capital and other equity for the three months ended March 31, 2024 and 2023. For the related information, please refer to Note 6(u) of the consolidated financial statements for the year ended December 31, 2023.

(i) Capital surplus

Balance of capital surplus at the reporting date were as follows:

		March 31, 2024	December 31, 2023	March 31, 2023
Additional paid-in capital	\$	9,234,813	9,234,813	9,234,813
Equity component of convertible bonds		639,583	639,583	639,583
Changes in ownership interests in subsidiaries		85,565	85,565	85,565
Changes in equity of associates accounted for using equity method		4,725	3,982	1,849
Employee stock options	_	3,245	3,245	3,245
	\$_	9,967,931	9,967,188	9,965,055

(ii) Retained earnings

The Company's Articles of Incorporation stipulate that 10% of the balance of annual income or earnings after deducting accumulated deficit, if any, must be set aside as a legal reserve and a special capital reserve is likewise appropriated or the annual income or earnings are retained in accordance with the relevant laws or regulations or as requested by the authorities, but the balance of such legal reserve reaches an amount equal to the paid-in capital, the appropriation to legal reserves is discontinued. Otherwise, the Company shall set aside at least 50% for shareholder, the distribution of remaining balance of the earnings should be further proposed by the Board of Directors and resolved by the shareholders' meeting. And the cash dividends should not lower than 10% of the total stockholders' dividends.

It is authorized the distributable dividends and bonuses or legal capital reserve and capital reserve in whole or in part may be paid in cash after a resolution has been adopted by a majority vote at a meeting of the Board of Directors attended by two-thirds of the total number of directors; and in addition thereto a report of such distribution shall be submitted to the shareholders' meeting.

As the Company is a technology and capital-intensive enterprise and is in its growth phase, it has adopted a more prudent approach in appropriating its remaining earnings as its dividend policy in order to sustain its long-term capital needs and thereby maintain continuous development and steady growth.

The appropriation of earning for 2022 had been approved in the meeting of Board of Directors held on March 9, 2023. The appropriation and dividends were as follows:

Cash dividends 2022 \$ 1,059,85

The related information mentioned above can be found on websites such as the Market Observation Post System.

(iii) Other equity interests, net of tax

The Group		diffe trai foreig sta	xchange erences on nslation of gn financial atements	Unrealized gains (losses) on financial assets at fair value through other comprehensive income
The Group Associates 166,895 - Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): - 573,266 Associates - (2,011 Cumulative gains (losses) reclassified to retained earnings on disposal of investments in equity instruments at fair value through other comprehensive income (net of tax) - 1,280 Balance as of March 31, 2024 \$ 358,223 3,120,197 Balance as of January 1, 2024 \$ 358,223 3,120,197 Foreign financial sests at fair value through other comprehensive income (net of tax): \$ 61,004 712,629 Foreign currency differences (net of tax): 32,085 - The Group 32,085 - Associates 33,776 - Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): 33,776 - Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): - 354,727	Balance as of January 1, 2024	\$	(12,053)	2,547,662
Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): The Group Associates Cumulative gains (losses) reclassified to retained earnings on disposal of investments in equity instruments at fair value through other comprehensive income (net of tax) Balance as of March 31, 2024 Balance as of March 31, 2024 Balance as of January 1, 2023 Foreign currency differences (net of tax): The Group Associates The Group Associates The Group Associates The Group Associates The Group Associates The Group	• • • • • • • • • • • • • • • • • • • •			
Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): The Group Associates Cumulative gains (losses) reclassified to retained earnings on disposal of investments in equity instruments at fair value through other comprehensive income (net of tax) Balance as of March 31, 2024 Balance as of March 31, 2024 Balance as of January 1, 2023 Foreign currency differences (net of tax): The Group Associates Unrealized gains (losses) on financial assets at fair value through other comprehensive income (net of tax): The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): The Group Associates The Group Associates The Group	-			-
value through other comprehensive income (net of tax): The Group Associates Cumulative gains (losses) reclassified to retained earnings on disposal of investments in equity instruments at fair value through other comprehensive income (net of tax) Balance as of March 31, 2024 Balance as of January 1, 2023 Foreign currency differences (net of tax): The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): The Group Associates The Group Associates The Group Associates The Group			203,381	-
Associates Cumulative gains (losses) reclassified to retained earnings on disposal of investments in equity instruments at fair value through other comprehensive income (net of tax) Balance as of March 31, 2024 Balance as of January 1, 2023 Foreign currency differences (net of tax): The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): The Group Associates The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): The Group Associates The Group Associates The Group Associates The Group				
Cumulative gains (losses) reclassified to retained earnings on disposal of investments in equity instruments at fair value through other comprehensive income (net of tax) Balance as of March 31, 2024 Exchange differences on translation of foreign financial assets at fair value through other omprehensive income Balance as of January 1, 2023 Foreign currency differences (net of tax): The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): The Group	The Group		-	573,266
investments in equity instruments at fair value through other comprehensive income (net of tax) Balance as of March 31, 2024 Sate and a sate and	Associates		-	(2,011)
Balance as of March 31, 2024 Exchange differences on translation of foreign financial sasets at fair value through other comprehensive income Balance as of January 1, 2023 Foreign currency differences (net of tax): The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): The Group	investments in equity instruments at fair value through other		_	1.280
Balance as of January 1, 2023 Foreign currency differences (net of tax): The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): The Group - 354,727	•	\$	358,223	
Foreign currency differences (net of tax): The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): The Group - 354,727		diffe tran foreig sta	echange erences on uslation of gn financial atements	Unrealized gains (losses) on financial assets at fair value through other comprehensive income
The Group 32,085 - Associates 33,776 - Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): The Group - 354,727	•	2	61,004	/12,629
Associates 33,776 - Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): The Group - 354,727	• • • • • • • • • • • • • • • • • • • •		22.095	
Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax): The Group - 354,727	•			-
• — — —	Unrealized gains (losses) on equity instruments at fair		33,170	-
7.1	The Group			354,727
Balance as of March 31, 2023 \$ 126,865 1,067,356	Balance as of March 31, 2023	\$	126,865	1,067,356

(v) Share-based payment

Except for the following disclosure, there were no significant changes for share-based payment for the three months ended March 31, 2024 and 2023. For the related information, please refer to Note 6(v) of the consolidated financial statements for the year ended December 31, 2023.

For the three months ended March 31, 2024 and 2023, the PBL recognized the compensation cost of \$2,172 thousand and \$5,514 thousand for the aforementioned ESOPs, respectively.

(w) Earnings per share ("EPS")

	For the three months ended	For the three months ended
	March 31, 2024	March 31, 2023
Basic earnings per share:		
Profit (loss) belonging to common shareholders	406,726	(401,811)
Weighted-average number of outstanding shares of common stock		
(in thousands shares)	423,940	423,940
Basic earnings per share (in dollars)	0.96	(0.95)
Diluted earnings per share:		
Profit (loss) belonging to common shareholders	406,726	(401,811)
Interest expense and other gains and losses on convertible bonds, net of tax		(107,001)
Profit (loss) belonging to common shareholders (diluted)	406,726	(508,812)
Weighted-average number of outstanding shares of common stock		
(in thousands shares)	423,940	423,940
Effect of potentially dilutive common stock		
Employee remuneration (in thousands shares)	206	-
Effect of conversion of convertible bonds (in thousands shares)		23,905
Weighted-average number of common stock (diluted) (in thousands shares)	424,146	447,845
Diluted earnings per share (in dollars)	0.96	(1.14)

For the three months ended March 31, 2024, the convertible bonds had anti-diluted effects if the bonds were converted, and hence the convertible was not included in the calculation of effect on potentially diluted common stock. Furthermore, for the three months ended March 31, 2023, the employee compensation had anti-diluted effects, and hence the employee compensation was not included in the calculation of effect on potentially diluted common stock.

(x) Revenue from contracts with customers

(i) Disaggregation of revenue

		For the	three months e	nded March 31	, 2024
		Segment- Foundry	Segment- Agriculture technology	Segment- Others (Note)	Total
Primary geographical markets:					
Asia	\$	3,114,047	102,231	1,390	3,217,668
Americas		767,057	-	12,478	779,535
Taiwan		240,226	1,675	26,452	268,353
Europe	_	176,845			176,845
	\$_	4,298,175	103,906	40,320	4,442,401
Main product/ services lines:	_				
Foundry	\$	4,292,227	-	-	4,292,227
Others	_	5,948	103,906	40,320	150,174
	\$ _	4,298,175	103,906	40,320	4,442,401

(Continued)

For the three months ended March 31, 2023

	For the three months ended whaten 31, 2023						
Segment- Foundry		Segment- Agriculture technology	Segment- Others (Note)	Total			
\$	1,592,954	109,647	184,939	1,887,540			
	643,063	-	10,543	653,606			
	120,892	791	23,431	145,114			
_	159,996		13,302	173,298			
\$	2,516,905	110,438	232,215	2,859,558			
_							
\$	2,516,129	-	-	2,516,129			
_	776	110,438	232,215	343,429			
\$	2,516,905	110,438	232,215	2,859,558			
	\$ _ \$	Segment-Foundry \$ 1,592,954 643,063 120,892 159,996 \$ 2,516,905 \$ 2,516,129 776	Segment-Foundry Segment-Agriculture technology \$ 1,592,954 109,647 643,063 - 120,892 791 159,996 - \$ 2,516,905 110,438 \$ 2,516,129 - 776 110,438	Segment-Foundry Segment-Agriculture technology Segment-Others (Note) \$ 1,592,954 109,647 184,939 643,063 - 10,543 120,892 791 23,431 159,996 - 13,302 \$ 2,516,905 110,438 232,215 \$ 2,516,129 - - 776 110,438 232,215			

Note: Segment-others were mainly general investment businesses, and their net investment profits and losses were recognized as operating revenue.

(ii) Balance of contracts

	N 	1arch 31, 2024	December 31, 2023	March 31, 2023	
Notes receivable	\$	1,544	1,351	839	
Accounts receivable		1,186,437	1,148,140	778,610	
Less: loss allowance		(60)	(825)	(1,928)	
	\$	1,187,921	1,148,666	777,521	
Contract liabilities	\$ <u></u>	497,636	563,765	309,002	

For details of notes and accounts receivable and allowance for impairment, please refer to Note 6(c).

The major change in the balance of contract liabilities is the difference between the time frame in the performance obligation to be satisfied and the payment to be received. The amount of revenue recognized for the three months ended March 31, 2024 and 2023 that was included in the contract liabilities balance at the beginning of the period was \$391,787 thousand and \$157,375 thousand, respectively.

(y) Employees' and directors' remuneration

According to the Company's Article of Incorporation, if there is any net profit after closing of a fiscal year, it shall be allocated according to the following principles:

- (i) Employees' remuneration: not less than 5% but no more than 10% shall be distributed in the form of shares or cash. Stock-type employee remuneration may be distributed to qualified employees of affiliates of the Company.
- (ii) Directors's remuneration: no more than 3%.

However, if there are any accumulated losses of the Company, the Company shall pre-reserve the amount to offset the loss. The distribution of employees' remuneration and directors's remuneration shall follow the special resolution by Board of Directors, and report it to the shareholders' meeting.

The Company estimated its employees' and directors' remuneration as follows:

	mon	ths ended	For the three months ended March 31, 2023
Employees' remuneration	\$	30,100	-
Directors' remuneration		6,300	
	\$	36,400	

The amount of employees' remuneration, and directors' remuneration were estimated based on profit before tax, net of the amount of the remuneration, deduct the accumulated loss and multiplied by the rule of Company's Article of Incorporation. The above remuneration was included in the operating costs and operating expenses of for the three months ended March 31, 2024. For the year end December 31, 2023, no remunerations to employees and directors were accrued due to the net loss before income tax incurred by the Company. The differences between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements, if any, shall be accounted for as changes in accounting estimates and recognized in profit or loss in the following year.

For the year ended December 31, 2022, the Company accrued and recognized its employees' remuneration amounting to \$149,000 thousand, and directors' remuneration amounting to \$38,000 thousand. There were no difference between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements. The related information mentioned above can be found on websites such as the Market Observation Post System.

(z) Non-operating income and expenses

	· • >	T	•
1	(i)) Interest	income

		moi	the three oths ended ch 31, 2024	For the three months ended March 31, 2023
	Interest income from bank deposits	\$	29,481	53,911
	Other interest income		44	33
	Interest income	\$	29,525	53,944
(ii)	Other income			
		mon	the three ths ended	For the three months ended March 31, 2023
	Dividend income	\$	7,330	6,750
	Rent income		9,990	10,512
	Other income	\$	17,320	17,262
(iii)	Other gains and losses			
		mon	the three ths ended ch 31, 2024	For the three months ended March 31, 2023
	Losses on disposals of property, plant and equipment	\$	-	(22,826)
	Foreign exchange losses		(20,690)	(6,447)
	Gains on financial assets or liabilities at fair value through profit or loss		47,609	155,785
	Gains on repurchases of bonds payable		-	15,316
	Gains on financial liabilities measured at amortized cost		253,828	-
	Others		1,207	(19,383)
	Other gains and losses	\$	281,954	122,445

(iv) Finance costs

	For mor Marc	For the three months ended March 31, 2023		
Interest expenses				
Bank borrowings	\$	210,901	149,213	
Bonds payable		2,914	34,178	
Lease liabilities		5,693	5,982	
Less: capitalized interest		(19,886)	(50,954)	
Subtotal		199,622	138,419	
Other finance costs		197	161	
Finance costs	\$	199,819	138,580	

(aa) Financial instruments

Except for the contention mentioned below, there was no significant change in the fair value of the Group's financial instruments and degree of exposure to credit risk, liquidity risk and market risk arising from financial instruments. For the related information, please refer to Note 6(aa) of the consolidated financial statements for the year ended December 31, 2023.

(i) Credit risk

1) Receivables and debt securities

For information on credit risk regarding notes and accounts receivable, please refer to Note 6(c).

Other financial assets measured at amortized cost include other receivables and time deposits. For related information of investment and impairment, please refer to Note 6(b) and Note 6(d).

All of these financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited 12 months expected losses.

(ii) Liquidity risk

The following were the contractual maturities of financial liabilities:

	Carrying amount	Contractual cash flows	Within 1 year	1-2 years	2-5 years	Over 5 years
As of March 31, 2024						
Non-derivative financial liabilities						
Secured bank loans	\$ 9,638,98	2 10,411,191	524,241	8,596,419	338,440	952,091
Unsecured bank loans	12,910,39	0 13,278,206	4,778,618	3,972,790	4,526,798	-
Notes and accounts payable	1,543,94	6 1,543,946	1,543,946	-	-	-
Other payables	1,820,40	1 1,820,401	1,820,401	-	-	-
Guarantee deposits received	118,92	6 118,926	349	8,577	110,000	-
Lease liabilities	971,57	7 1,150,903	124,185	113,598	239,862	673,258
	\$ 27,004,22	28,323,573	8,791,740	12,691,384	5,215,100	1,625,349

(Continued)

	Carry amou	0	Contractual cash flows	Within 1 year	1-2 years	2-5 years	Over 5 vears
As of December 31, 2023							
Non-derivative financial liabilities							
Secured bank loans	\$ 9,30	4,156	10,432,864	521,175	8,592,189	339,854	979,646
Unsecured bank loans	13,74	3,277	14,127,706	3,181,583	6,427,642	4,143,481	375,000
Bonds payable	4,74	3,834	4,724,953	4,724,953	-	-	-
Notes and accounts payable	1,36	2,255	1,362,255	1,362,255	-	-	-
Other payables	2,16	9,969	2,169,969	2,169,969	-	-	-
Guarantee deposits received	11	9,557	119,557	1,141	8,416	110,000	-
Lease liabilities	95	8,073	1,139,070	113,567	110,939	249,701	664,863
	\$ 32,40	1,121	34,076,374	12,074,643	15,139,186	4,843,036	2,019,509
As of March 31, 2023	-						
Non-derivative financial liabilities							
Secured bank loans	\$ 7,99	9,807	8,946,710	430,832	414,397	8,101,481	-
Unsecured bank loans	10,65	7,247	10,904,091	2,601,907	5,330,022	2,751,925	220,237
Bonds payable	10,56	8,792	10,628,430	10,628,430	-	-	-
Accounts payable	72	4,935	724,935	724,935	-	-	-
Other payables	2,90	0,174	2,900,174	2,900,174	-	-	-
Guarantee deposits received	11	9,347	119,347	612	8,735	-	110,000
Lease liabilities	1,01	3,286	1,212,615	119,520	105,755	268,842	718,498
	\$ 33,98	3,588	35,436,302	17,406,410	5,858,909	11,122,248	1,048,735

The Group did not expect that the cash flows included in the maturity analysis could occur significantly earlier or at significantly different amounts.

(iii) Currency risk

1) Exposure to currency risk

The Group's significant exposure to foreign currency risk were as follows:

	March 31, 2024			March 31, 2024 December 31, 2023					March 31, 2023			
		Foreign currency	Exchange rate	NT\$	Foreign currency	Exchange rate	NT\$	Foreign currency	Exchange rate	NT\$		
Financial assets												
Monetary items												
USD	\$	123,992	32.00	3,967,748	277,939	30.71	8,535,521	291,188	30.45	8,866,668		
EUR		296	34.46	10,199	70	34.02	2,390	81	33.15	2,699		
JPY		470,263	0.2115	99,461	210,115	0.2173	45,658	377,197	0.2288	86,303		
GBP		11	40.39	450	11	39.18	435	11	37.67	416		
HKD		58	4.089	238	59	3.931	242	58	3.879	226		
RMB		65	4.41	289	66	4.33	285	66	4.43	290		
SGD		1	23.72	21	1	23.31	20	1	22.91	20		
			\$	4,078,406		\$	8,584,551		\$	8,956,622		
Non-monetary items												
USD	\$	15,927	32.00	509,421	15,265	30.71	468,788	18,186	30.45	553,774		
RMB		222,538	4.41	979,683	245,907	4.33	1,062,856	254,679	4.43	1,126,806		
			\$	1,489,104		\$	1,531,644		\$	1,680,580		

	 N	Iarch 31, 2024		De	cember 31, 202	3	March 31, 2023			
	Foreign urrency	Exchange rate	NT\$	Foreign currency	Exchange rate	NT\$	Foreign currency	Exchange rate	NT\$	
Financial liabilities										
Monetary items										
USD	\$ 240,029	32.00	7,680,943	236,181	30.71	7,253,131	236,627	30.45	7,205,307	
EUR	353	34.46	12,150	452	34.02	15,386	139	33.15	4,610	
JPY	491,911	0.2115	104,039	665,539	0.2173	144,622	342,224	0.2288	78,301	
		\$	7,797,132		\$	7,413,139		\$	7,288,218	

2) Sensitivity analysis

The Group's exposure to foreign currency risk arises from the translation of the foreign currency exchange gains and losses on cash and cash equivalents, notes and accounts receivable, other receivables, financial assets at fair value through profit or loss, notes and accounts payable, other payables, long-term borrowings, etc. that are denominated in foreign currency. A strengthening (weakening) 5 % of appreciation (depreciation) of the TWD against the USD, EUR, GBP, JPY, HKD, RMB, SGD, etc. for the three months ended March 31, 2024 and 2023 would have increased (decreased) the net profit after tax by \$110,718 thousand and \$88,887 thousand, respectively. The analysis assumes that all other variables remain constant.

3) Exchange gains or losses

Since the Group has many kinds of functional currency, the information on foreign exchange gains (losses) on monetary items is disclosed by total amount. For three months ended March 31, 2024 and 2023, foreign exchange gains (losses) (including realized and unrealized portions) amounted to \$20,690 thousand and \$6,447 thousand, respectively.

(iv) Interest rate risk

Please refer to the attached note for the liquidity risk and the Group's interest rate exposure to its financial liabilities.

The following sensitivity analysis is based on the risk exposure to interest rates on the nonderivatives financial instruments on the reporting date. For variable rate instruments, the sensitivity analysis assumes the variable rate liabilities are outstanding for the whole year on the reporting date.

If the interest rate increases (decreases) by 0.5%, the Group's net profit after tax would have increased (decreased) by \$24,413 thousand and \$18,668 thousand for the three months ended March 31, 2024 and 2023, respectively, all other variable factors that remain constant. This is mainly due to the Group's borrowing in floating rates.

(v) Fair value

1) Financial instrument classifications and fair values

The fair value of financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income are measured on a recurring basis. The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy were as follows; however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities disclosure of fair value information is not required.

		March 31, 2024				
					value	
Financial assets at fair value through profit or loss	Ca	rrying value	Level 1	Level 2	Level 3	Total
ς,						
Stocks listed on domestic markets	\$	439,989	439,989	-	-	439,989
Funds and investment		137,527	137,527	-	-	137,527
Private fund		1,401,285	<u> </u>	-	1,401,285	1,401,285
Subtotal	\$	1,978,801	577,516		1,401,285	1,978,801
Financial assets at fair value through other comprehensive	income					
Stocks listed on domestic and foreign markets	\$	3,828,675	3,828,675	-	-	3,828,675
Non-public stocks		369,170		-	369,170	369,170
Subtotal	\$	4,197,845	3,828,675	-	369,170	4,197,845
Financial assets measured at amortized cost						
Cash and cash equivalents (Note)	\$	5,592,016	-	-	-	-
Financial assets at amortized cost (Note)		135,930	-	-	-	-
Notes and accounts receivable (Note)		1,187,921	-	-	-	-
Other receivables (Note)		31,431	-	-	-	-
Other non-current assets (Note)		335,014		-		-
Subtotal	<u>\$</u>	7,282,312		-		-
Financial liabilities measured at amortized cost						
Bank loans (Note)	\$	22,549,372	-	-	-	-
Notes and accounts payable (Note)		1,543,946	-	-	-	-
Other payables (Note)		1,820,401	-	-	-	-
Guarantee deposits received (Note)		118,926	-	-	-	-
Lease liabilities (Note)		971,577		-		-
Subtotal	\$	27,004,222	<u> </u>	-		

	December 31, 2023				
	Carrying value	Level 1	Fair va	Level 3	Total
Financial assets at fair value through profit or loss	Carrying value	<u> </u>	Ecvel 2	Levers	Total
Stocks listed on domestic markets	\$ 516,759	516,759	-	-	516,759
Funds and investment	137,088	137,088	-	-	137,088
Private fund	1,334,075	-	-	1,334,075	1,334,075
Subtotal	\$ 1,987,922	653,847		1,334,075	1,987,922
Financial assets at fair value through other comprehensive income	; <u>====================================</u>				
Stocks listed on domestic and foreign markets	\$ 3,278,125	3,278,125	-	-	3,278,125
Non-public stocks	374,409	-	-	374,409	374,409
Subtotal	\$ 3,652,534	3,278,125		374,409	3,652,534
Financial assets measured at amortized cost					
Cash and cash equivalents (Note)	\$ 10,325,709	-	-	-	-
Notes and accounts receivable (Note)	1,148,666	_	_	_	_
Other receivables (Note)	19,999	_	_	_	_
Other non-current assets (Note)	338,244	_	_	_	_
Subtotal	\$ 11,832,618				_
Financial liabilities at fair value through profit or loss	11,002,010				
Derivative financial liabilities	\$ 231,774	_	231,774	_	231,774
Financial liabilities measured at amortized cost	231,774		231,774		231,774
Bank loans (Note)	\$ 23,047,433				
Bonds payable (Note)	4,743,834	-	-	-	-
		-	-	-	-
Notes and accounts payable (Note)	1,362,255	-	-	-	-
Other payables (Note)	2,169,969	-	-	-	-
Guarantee deposits received (Note)	119,557	-	-	-	-
Lease liabilities (Note)	958,073				-
Subtotal	\$ 32,401,121	 =	 =	 =	-
		М	larch 31, 2023		
	Comming value	Level 1	Fair va	llue Level 3	Total
Financial assets at fair value through profit or loss	Carrying value	Level 1	Level 2	Level 5	1 Otal
Stocks listed on domestic markets	\$ 482,729	482,729	-	-	482,729
Funds and investment	111,617	111,617	-	_	111,617
Private fund	1,400,193	- -	-	1,400,193	1,400,193
Subtotal	\$ 1,994,539	594,346		1,400,193	1,994,539
Financial assets at fair value through other comprehensive income		05 1,0 10		1,100,120	1,551,005
Stocks listed on domestic and foreign markets	\$ 1,547,641	1,547,641	_	_	1,547,641
Non-public stocks	648,466	-	_	648,466	648,466
Subtotal	\$ 2,196,107	1,547,641		648,466	2,196,107
Financial assets measured at amortized cost	2,170,107	1,347,041		040,400	2,170,107
Cash and cash equivalents (Note)	\$ 10,406,167				
Notes and accounts receivable (Note)	777,521	-	-	-	-
· · ·		-	-	-	-
Other receivables (Note)	42,076	-	-	-	-
Other non-current assets (Note)	491,421	- -	- -	- -	-
Subtotal Figure 1 Light Haling at 6 in order through the 6 feet less	\$ <u>11,717,185</u>	- -	- -		-
Financial liabilities at fair value through profit or loss			20.5 502		****
Derivative financial liabilities	\$ 306,682	- -	306,682		306,682

	March 31, 2023					
				Fair		
	_Ca	rrying value	Level 1	Level 2	Level 3	Total
Financial liabilities measured at amortized cost						
Bank loans (Note)	\$	18,657,054	-	-	-	-
Bonds payable (Note)		10,568,792	-	-	-	-
Accounts payable (Note)		724,935	-	-	-	-
Other payables (Note)		2,900,174	-	-	-	-
Guarantee deposits received (Note)		119,347	-	-	-	-
Lease liabilities (Note)		1,013,286	-			
Subtotal	\$	33,983,588				

Note: The information on fair value is not disclosed since the carrying amount is a reasonable approximation of fair value.

2) Valuation techniques of financial instrument not valued at fair value

The valuation techniques of the Group's financial instruments not valued at fair value by using the methods and assumptions are as follows:

• Financial assets measured at amortized cost and financial liabilities measured at amortized cost.

If recent transaction prices or market maker quotes are available, the fair value is based on such information. If there is no quoted market price available, the fair value is determined by using valuation techniques and calculated as the present value of the estimated cash flows.

- 3) Valuation techniques of financial instruments valued at fair value
 - a) Non-derivative instruments

The fair value of financial assets and liabilities traded in an active market is based on the quoted market prices. The quotation, which is published by the main exchange center or that which was deemed to be a public bond by the Treasury Bureau of Central Bank, is included in the fair value of the listed securities instruments and the debt instruments in active markets with open bid.

A financial instrument is regarded as the quoted price in an active market if the quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency; and if those prices represent the actual and regularly occurring market transactions on an arm's length basis. Otherwise, the market is deemed to be inactive. Normally, a market is considered to be inactive when:

- The bid-ask spread is increasing; or
- The bid-ask spread varies significantly; or
- There has been a significant decline in trading volume.

When the financial instrument of the Group is traded in an active market, its fair value is illustrated by the category and nature as follows:

- Financial assets and liabilities with standard terms and conditions and traded in an active market, for example, investment in stock of listed companies: the fair value is based on the market quoted price.
- Close-end funds with standard terms and conditions, such as money market funds; investors can require the investment trust company to redeem the fund at any time. The fair value is based on the net value of the fund.

Except for the above-mentioned financial instruments traded in an active market, the fair value is based on the valuation techniques or the quotation from the counter-party. The fair value refers to the current fair value of the other financial instruments with similar conditions and characteristics, using a discounted cash flow analysis or other valuation techniques, such as calculations of using models (for example, applicable yield curve from Taipei Exchange, or average quoted price on interest rate of commercial paper from Reuters), based on the information acquired from the market at the balance sheet date.

When the financial instrument of the Group is not traded in an active market, its fair value is determined as follows:

- The fair value is determined based on the ratio of the quoted market price of the comparative listed company and its book value per share and its sales revenue per share. Also, the fair value is discounted for its lack of liquidity in the market.
- The fair value is determined by using the asset-based approach, whose assumptions are based on the market approach, income approach, cost approach or other valuation methods according to the nature of the assets or liabilities of the subject companies.

b) Derivative instruments

The fair value is determined by using the models that are acceptable to the market participants, for example, discounted cash flow analyses or option pricing models. Forward exchange contracts are measured using quoted forward exchange rates. The fair value of structured interest derivative financial instruments is determined by using the proper option pricing models, such as Black-Scholes model, or other valuation technique, such as Monte Carlo simulation.

4) Level transfers of financial instruments

For the three months ended March 31, 2024 and 2023, there was no transfer of financial instrument.

5) Movement of level 3

	Fair value through profit or loss		Fair value through other comprehensive income Unquoted	
		Private fund	equity instruments	
Balance as of January 1, 2024	\$	1,334,075	374,409	
Total gains or losses:				
Recognized in profit and loss		48,981	-	
Recognized in other comprehensive income		-	24,190	
Purchased		26,345	-	
Disposals		-	(30,300)	
Capital reduction		(8,116)	-	
Effect of changes in foreign exchange rates	_		871	
Balance as of March 31, 2024	\$_	1,401,285	369,170	
Balance as of January 1, 2023	\$	1,369,943	480,320	
Total gains or losses:				
Recognized in profit and loss		16,968	-	
Recognized in other comprehensive income		-	168,405	
Purchased		15,490	-	
Capital reduction		(2,208)	-	
Effect of changes in foreign exchange rates	_		(259)	
Balance as of March 31, 2023	\$ <u>_</u>	1,400,193	648,466	

The preceding gains and losses were recognized as "other gains and losses" and "unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive income". As of March 31, 2024 and 2023, the related information of the assets which were still held by the Group were as follows:

	mor	the three of this ended och 31, 2024	For the three months ended March 31, 2023
Total gains or losses			
Profit or loss (recognized as other gains and losses)	\$	48,981	16,968
Other comprehensive income (recognized as unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive			
income)		(5,239)	168,405

6) Quantified information on significant unobservable inputs (Level 3) used in fair value measurement

The Group's financial instruments that use Level 3 inputs to measure fair value include "financial assets at fair value through profit or loss – private funds" and "financial assets at fair value through other comprehensive income – equity investments."

Most of the fair value measurements categorized within Level 3 use the single and significant unobservable input. Equity investments without an active market contains multiple significant unobservable inputs. The significant unobservable inputs of the equity investments are independent from each other, as a result, there is no relevance between them.

Quantified information of significant unobservable inputs was as follows:

Item Financial assets at fair value through other comprehensive income – equity investments without an active market	Valuation technique ● Comparable companies approach	Significant unobservable inputs Price-book ratio (as of March 31, 2024, December 31 and March 31, 2023 were 1.61~2.19, 1.71~4.24 and 1.68~4.81, respectively) Market liquidity discount rate (as of March 31, 2024, December 31 and March 31, 2023 were both 20%)	Inter-relationships between significant unobservable inputs and fair value measurement The higher the price-book ratio, the higher the fair value The higher the market liquidity discount rate, the lower the fair value
	Net asset value method	Net asset value	• The higher the net assets value, the higher the fair value
Financial assets at fair value through profit or loss – private fund	Net asset value method	Net asset value	• The higher the net assets value, the higher the fair value

7) Sensitivity analysis of reasonably possible alternative assumptions for fair value measurements in Level 3 of the fair value hierarchy

The fair value measurements of the Group's financial instruments are reasonable. However, changes in the use of valuation models or valuation variables may affect the estimations. For fair value measurements in Level 3, a fluctuation in the valuation variable by 5% would have the following effect:

				Effects of changes in fair value on profit or loss		Effects of changes in far value on other comprehensive income	
	Inputs	Increase or decrease]	Favorable	Unfavorable	Favorable	Unfavorable
March 31, 2024			_				
Financial assets at fair value through profit or loss							
Private fund	Net asset value	5%	\$	70,064	(70,064)	-	-
Financial assets at fair value through other comprehensive income							
Equity investments without an active market	Price-book ratio	5%		-	-	11,922	(11,922)
"	Market liquidity discount rate	5%		-	-	11,922	(11,922)
"	Net asset value	5%		-	-	6,537	(6,537)
December 31, 2023							
Financial assets at fair value through profit or loss							
Private fund	Net asset value	5%		66,704	(66,704)	-	-
Financial assets at fair value through other comprehensive income							
Equity investments without an active market	Price-book ratio	5%		-	-	12,021	(12,021)
"	Market liquidity discount rate	5%		-	-	12,021	(12,021)
"	Net asset value	5%		-	-	6,700	(6,700)
March 31, 2023							
Financial assets at fair value through profit or loss							
Private fund	Net asset value	5%		70,010	(70,010)	-	-
Financial assets at fair value through other comprehensive income							
Equity investments without an active market	Price-book ratio	5%		-	-	23,585	(23,585)
II.	Market liquidity discount rate	5%		-	-	23,585	(23,585)
"	Net asset value	5%		-	-	8,838	(8,838)

The favorable and unfavorable effects represent the changes in fair value, and fair value is based on a variety of unobservable inputs calculated using a valuation technique. The analysis above only reflects the effects of changes in a single input, and it does not include the inter-relationships with another input.

(ab) Management of financial risk

There was no significant change in the Group's objective and policies for the management of financial risk of the consolidated financial statements for the three months ended March 31, 2024 which compared with the consolidated financial statements Note 6(ab) for the year ended December 31, 2023.

(ac) Capital management

The Board of Directors policy is to maintain a strong capital base to maintain to confidence of investors, creditors and market, and to sustain future development of the business. For the goal of business sustainability, the Group monitors the expansion plan as well as the level of dividends to ordinary shareholders.

As of March 31, 2024, December 31 and March 31, 2023, the Group's return on common equity was 4.70%, (0.24)% and (4.90)%, respectively. The Group's debt ratio at the reporting date were as follows:

	March 31,	December 31,	March 31,
	2024	2023	2023
Debt ratio	43.49 %	48.89 %	50.68 %

(ad) Financing activity

Reconciliations of liabilities arising from financing activities were as follows:

				Non-cash changes			
	J	anuary 1, 2024	Cash flows	Interest expense	Others	Amortization of arranger fee of syndicated loan	March 31, 2024
Short-term borrowings	\$	21,129	(15,478)	-	-	-	5,651
Long-term borrowings		23,026,304	(832,887)	-	339,719	10,585	22,543,721
Bonds payable		4,743,834	(4,724,694)	2,914	(22,054)	-	-
Guarantee deposit received		119,557	(631)	-	-	-	118,926
Lease liabilities	_	958,073	(20,589)	5,693	28,400		971,577
Total liabilities from financing activity	\$	28,868,897	(5,594,279)	8,607	346,065	10,585	23,639,875
					Non-cash changes		
	J	anuary 1, 2023	Cash flows	Interest expense	Others	Amortization of arranger fee of syndicated loan	March 31, 2023
Short-term borrowings	\$	-	15,957	-	-	-	15,957
Long-term borrowings		17,601,445	1,089,764	-	(59,118)	9,006	18,641,097
Bonds payable		10,669,555	-	34,178	(134,941)	-	10,568,792
Guarantee deposit received		119,299	48	-	-	-	119,347
Lease liabilities (Note)	_	1,028,402	(22,869)	5,982	1,771		1,013,286
Total liabilities from financing activity	\$_	29,418,701	1,082,900	40,160	(192,288)	9,006	30,358,479

(7) Related-party transactions:

(a) Names and relationship with related parties

The followings are entities that have had transactions with related party during the periods covered in the consolidated financial statements:

Name of related party	Relationship with the Group
Jiangsu CM/Chainwin Agriculture Development Co., Ltd. (abbrev.	Associates
Jiangsu CM/Chainwin)	
ITEQ Corporation (abbrev. ITEQ)	Associates
Taoyuan i-Fare Charity Foundation	Other related parties

- (b) Significant transactions with related parties
 - (i) Operating expenses

The amounts of operating expenses by the Group from related parties were as follows:

For the three	For the three
months ended	months ended
March 31, 2024	March 31, 2023
\$	3,161

Other related parties

(ii) Guarantee

As of March 31, 2024, December 31, and March 31, 2023, Chainwin Cayman had provided a guarantee for loans amounting to US\$7,350 thousand (\$235,200 thousand, \$225,719 thousand and \$223,808 thousand, respectively) to its associate, Jiangsu CM/Chainwin.

(iii) Leases

The Group leased the office and factories to its associate, ITEQ, and the rent income received monthly is based on the nearby office and factories rental rates. The amount of rent income is \$7,943 thousand and \$7,717 thousand for the three months ended March 31, 2024 and 2023, respectively. The preceding rent payment has been received. The guarantee deposits received amounted to \$110,000 thousand as of March 31, 2024, December 31, and March 31, 2023.

(c) Transactions with key management personnel

Key management personnel compensation was comprised as below:

	mon	ths ended	For the three months ended
	Marc	ch 31, 2024	March 31, 2023
Short-term employee benefits	\$	61,986	41,960
Post-employment benefits		314	314
	\$	62,300	42,274

(8) Pledged assets:

The carrying amounts of pledged assets were as follows:

Pledged assets	Pledged to secure		March 31, 2024	December 31, 2023	March 31, 2023
Other non-current assets	Land, plant, and dormitory lease guarantee	\$	23,556	23,556	23,556
Other non-current assets	Bank borrowings		192,389	184,630	170,275
Other non-current assets	Gas deposits		4,700	4,700	4,700
Other non-current assets	Customs guarantee with its interest		20,981	20,981	20,736
Other non-current assets	Seized funds and court security deposits		-	9,952	123,709
Property, plant and	Bank borrowings				
equipment		_	3,524,864	3,549,899	2,132,518
Total		\$_	3,766,490	3,793,718	2,475,494

(9) Commitments and contingencies:

(a) Contingencies: None.

(b) Commitment:

(i) The unrecognized commitment of acquisition of plant expansion and machinery equipment was as follows:

		March 31, 2024	December 31, 2023	March 31, 2023
The unrecognized amount	<u>\$</u>	4,183,710	4,332,398	5,479,883

(ii) The unused letters of credit was as follows:

		March 31, 2024	December 31, 2023	March 31, 2023
The unused letters of credit	\$ _	3,405	17,493	

(10) Losses due to major disasters: None.

(11) Subsequent events: None.

(12) Other:

(a) The followings were the summary statement of employee benefits, depreciation and amortization expenses by function:

	For the three	e months ended 2024	March 31,	For the three months ended March 31, 2023					
	Classified as operating costs	Classified as operating expenses	Total	Classified as operating costs	Classified as operating expenses	Total			
Employee benefits									
Salaries	592,376	250,708	843,084	535,583	235,112	770,695			
Labor and health insurance	56,776	19,331	76,107	60,843	20,814	81,657			
Pension	24,644	10,409	35,053	25,749	11,329	37,078			
Director remuneration	-	9,362	9,362	-	12	12			
Others	24,721	7,815	32,536	25,438	6,005	31,443			
Depreciation	953,570	215,968	1,169,538	862,993	214,192	1,077,185			
Amortization	7,544	19,825	27,369	7,819	21,625	29,444			

(b) Seasonality of operations:

The Group's operations were not affected by seasonality or cyclicality factors.

(13) Other disclosures:

(a) Information on significant transactions:

The following were the information on significant transactions required by the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" for the Group for the three months ended March 31, 2024:

- (i) Loans to other parties: Please refer to schedule A.
- (ii) Guarantees and endorsements for other parties: Please refer to schedule B.
- (iii) Securities held as of March 31, 2024 (excluding investment in subsidiaries, associates and joint ventures): Please refer to schedule C.
- (iv) Individual securities acquired or disposed of with accumulated amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital: None.
- (v) Information on acquisition of real estate with purchase amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital: Please refer to schedule D.
- (vi) Information on disposal of real estate with amounts exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital: None.

- (vii) Information regarding related-parties purchases and/or sales with amounts exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital: None.
- (viii) Information regarding receivables from related-parties exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital: Please refer to schedule E.
- (ix) Information regarding trading in derivative financial instruments: Please refer to Note 6(b).
- (x) Business relationships and significant intercompany transactions: Please refer to schedule F.
- (b) Information on investments: Please refer to schedule G.
- (c) Information on investment in mainland China: Please refer to schedule H.
- (d) Information on major shareholders: Please refer to schedule I.

(14) Segment information:

- (a) The Group's reportable segment is the foundry segment, and agriculture technology segment. The segment engages separately in researching, developing, manufacturing, selling of GaAs wafers and developing hog farming technology and trading, etc., respectively.
 - Other operating segments are mainly engaged in investment activities and gene chip and testing, which do not exceed the quantitative thresholds to be reported.
- (b) Operating segment profit or loss (includes reportable segment revenue and expenses), segment assets, segment liabilities, and their measurement and reconciliations for the three months ended March 31, 2024 and 2023, the reportable amount is same as that in the report used by the operating decision maker and the operating segment accounting policies are same as the ones described in Note 4 "significant accounting policies" were as follows:

				1	Reconciliation	
For the three months ended March 31, 2024 Revenue:		Foundry	Agriculture technology	Others	and elimination	Total
Revenue from external customers	\$_	4,298,175	103,906	40,320		4,442,401
Interest expenses	\$	47,491	150,699	1,629		199,819
Depreciation and amortization	\$	996,454	192,405	8,048		1,196,907
Share of profit (loss) of associates and joint ventures accounted for using equity method	\$ _	10,836	(18,129)	(8,641)		(15,934)
Other material non-cash items:				_		
Reportable segment profit or loss	\$_	656,624	(340,424)	(132,635)		183,565
Assets:						
Capital expenditures in non-current assets	\$_	281,998	36,393	648		319,039

For the three months ended March 31, 2023 Revenue:		Foundry	Agriculture technology	Others	Reconciliation and elimination	Total
Revenue from external customers	\$_	2,516,905	110,438	232,215		2,859,558
Interest expenses	\$	48,510	88,460	1,610	_	138,580
Depreciation and amortization	\$	921,919	175,887	8,823	_	1,106,629
Share of profit (loss) of associates and joint ventures accounted for using equity method	\$_	17,724	(33,663)	18,974		3,035
Reportable segment profit or loss	\$	(546,063)	(211,615)	162,925	_	(594,753)
Assets:	_					
Capital expenditures in non-current assets	\$_	444,332	121,975	4,325		570,632

For the three months ended March 31, 2024 and 2023, reportable segment profit or loss excludes non-operating income and expenses, amounting to \$125,155 thousand and \$39,132 thousand, respectively.

Schedule A Loans to other parties:

(In thousands of Dollars)

Number (Note 1)	I Name of lender	Name of borrower	Account name		Highest balance of financing to other parties during the period (Note 2)	Ending balance (Note 2)	Actual amount drawn down		Purposes of fund financing for the borrower (Note 3)	Reasons for short-term financing	Allowance for bad debts		ateral	Individual funding loan limits (Note 4)	Maximum limit of fund financing (Note 4)	Remark
					the period (Note 2)				(Note 3)			Item	Value			
1	Chainwin Biotech and Agrotech	Jiangsu Chainwin Kang Yuan Agricultural	Other receivables	Y	896,000	896,000	896,000	1%	2 -	Working	-	None	-	Net equity 20%=	Net equity 40%=	(Note 6)
	(Cayman Islands) Co., Ltd.	Development Co., Ltd.			(USD 28,000)	(USD 28,000)	(USD 28,000)			Capital				1,242,747	2,485,495	

Note 1: Company numbering as follows:

Issuer-0

Investee starts from 1

Note 2: The credit amount to lending.

Note 3: Purposes of lending were as follows:

- 1. Business relationship
- 2. Short-term financing

Note 4: Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s operating procedures of financing to other parties:

- 1. The loan limit to an individual party:(1) the total amount for lending to a company having business relationship with Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. shall not exceed their previous or current's total purchasing or sales amount (whichever is higher).
- (2) the total amount for lending to a company having short-term funding needs shall not exceed 20% of Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s equity based on its most recent audited or reviewed financial statements by a certified accountant.

 2. The maximum loans to other parties limit provided by Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. to other parties should not exceed 40% of its equity based on its most recent audited or reviewed financial statements by a certified accountant.
- Note 5: The aforementioned amount was translated at the exchange rate on the balance sheet date from USD to TWD for TWD 32.00.
- Note 6: The amount of the transaction had been offset in the consolidated financial statements.

Schedule B Guarantees and endorsements for other parties:

(In thousands of Dollars)

		Counter-party of guarantee and endorses	ment	Limitation on		Balance of		Downster	Ratio of				
Number (Note 1)	Name of guarantor	Name	Relationship with the Company (Note 2)	amount of guarantees and endorsements for a specific enterprise (Note 3)(Note 4)	Highest balance of guarantees and endorsements during the period (Note 3)	guarantees and	Actual usage amount	Property pledged for guarantees and endorsements (Amount)	accumulated amounts of guarantees and endorsements to net worth of the latest financial statements	Maximum amount for guarantees and endorsements (Note 3)(Note 4)	Parent company endorsements/ guarantees to subsidiary (Note 6)	Subsidiary endorsements/ guarantees to parent company (Note 6)	Endorsements/ guarantees to the companies in mainland China (Note 6)
0	The Company	Chainwin Biotech and Agrotech (Cayman Islands)	2	17,652,098	2,114,560	2,114,560	1,600,000	-	5.99%	Net equity 50%=	Y	-	-
0	"	Co., Ltd. Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	2	17,652,098	2,162,176	2,162,176	1,920,000	-	6.12%	17,652,098 Net equity 50%= 17,652,098	Y	-	Y
0	"	Jiangsu Win Yield Agriculture Development Co., Ltd.	2	17,652,098	3,641,088	3,641,088	3,520,000	-	10.31%	Net equity 50%= 17,652,098	Y	-	Y
0	"	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	2	17,652,098	1,591,360	1,591,360	1,440,000	-	4.51%	Net equity 50%= 17,652,098	Y	-	Y
0	"	Jiangsu Win Fortune Agrichture Development Co., Ltd.	2	17,652,098	30,272	30,272	-	-	0.09%	Net equity 50%= 17,652,098	Y	-	Y
0	"	Jiangsu Win Boutique Agriculture Development Co. Ltd.	2	17,652,098	30,272	30,272	-	-	0.09%	Net equity 50%= 17,652,098	Y	-	Y
0	//	Jiangsu Win Sunlight Agriculture Development Co. Ltd.	2	17,652,098	30,272	30,272	-	-	0.09%	Net equity 50%= 17,652,098	Y	-	Y
1	Chainwin Biotech and Agrotech	Jiangsu CM/Chainwin Agriculture	6	1,864,121	235,200	235,200	-	-	3.79%	Net equity 50%=	-	-	Y
1	(Cayman Islands) Co., Ltd.	Development Co., Ltd.		(USD 58,253)	` '	(USD 7,350)	5 (51	(4,000	0.020/	3,106,869			v
1	"	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	2	1,864,121 (USD 58,253)	57,600 (USD 1,800)	57,600 (USD 1,800)	5,651 (USD 177)	64,000 (USD 2,000)	0.93%	Net equity 50%= 3,106,869	-	-	Y

Note 1: Company numbering as follows:

- 1. Issuer -0
- 2. Investee starts from 1
- Note 2: The 7 types of relationship between the guarantee and the guarantor were as follows:
 - 1. For entities the guarantor has business transaction with.
 - 2. For entities in which the guarantor, directly or indirectly, owned more than 50% of their shares.
 - 3. For entities who owned, directly or indirectly, more than 50% in total of the guarantor's shares.
 - 4. For entities in which the guarantor, directly or indirectly, owned more than 90% of their shares.
 - 5. Fulfillment of contractual obligation by providing mutual endorsements and guarantees for peer or joint builders in order to undertake a construction project.
 - 6. For entities who are guaranteed and endorsed by all capital contributing shareholders in proportion to each of their shareholder's percentage.
 - 7. Performance guarantee in which entities within the same industry provide among themselves joint and several securities by entering into sales agreement with each other for pre-construction project pursuant to Company Protection Act.
- Note 3: The Company's operating procedures of guarantee and endorsement were as follows:
 - 1. The guarantees and endorsements limit provided by the Company to other parties should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant. The individual guarantee amount should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
 - 2. The guarantees and endorsements limit provided by the Company and its subsidiaries to other parties should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant. The individual guarantee amount should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
 - 3. The Company endorses and guarantees the bank loans of its subsidiaries, including Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd., Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd., Jiangsu Win Yield Agriculture Development Co., Ltd., Jiangsu Win Fortune Agriculture Development Co., Ltd., Jiangsu Win Sunlight Agriculture Development Co. Ltd., with the total amount not exceeding US\$300,000 thousand. In the second quarter of 2023, the applications of adjustment for the individual amount of each subsidiary had been approved by the banks, without changing the overall total amount of the guarantee and endorsement, resulting in the highest balance of guarantees and endorsements during the period of each company to be based on the ratio of each borrower's balance of guarantees and endorsements to the total amount as of the reporting date.
- Note 4: Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s operating procedures of guarantee and endorsement were as follows:
 - 1. The individual guarantee amount should not exceed 30% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
 - 2. The guarantees and endorsements limit provided by Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. to other parties should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
- Note 5: The aforementioned amount was translated at the exchange rate on the balance sheet date from USD to TWD and RMB to USD for TWD 32.00 and USD 0.1378, respectively.
- Note 6: Fill in "Y" for those cases of provision of endorsements/ guarantees by listed parent company to subsidiary, provision by subsidiary to listed parent company, and provision to the party in mainland China.

Schedule C Securities held as of March 31, 2024 (excluding investment in subsidiaries, associates and joint ventures):

(In thousands of New Taiwan Dollars)

	Category and	Relationship			Ending	balance		
Name of holder	name of security	with the company	Account name	Shares/ Units (in thousands)	Carrying value	Percentage of ownership (%)	Fair value	Remark
The Company	Lin BioScience, Inc./Stock	None	Current financial assets at fair value through profit or loss	55	4,868	0.07	4,868	
WIN Venture Capital Corp.	Capital Money Market Fund	"	"	3,763	62,618	-	62,618	
WIN Chance Investment Corp.	Capital Money Market Fund	"	"	1,102	18,342	-	18,342	
WIN Earn Investment Corp.	Capital Money Market Fund	"	"	3,399	56,567	-	56,567	
					142,395		142,395	
The Company	MagiCapital Fund II L.P.	//	Non-current financial assets at fair value through profit or loss	-	299,096	5.81	299,096	1
"	CDIB Capital Growth Partners L.P.	//	ıı ,	-	151,405	3.30	151,405	
"	CDIB Capital Healthcare Ventures II L.P.	//	ıı ,	-	59,665	1.61	59,665	
"	Fuh Hwa Oriental Fund	//	ıı ,	15,000	22,080	-	22,080	
"	Fuh Hwa Smart Energy Fund	//	ıı ,	12,000	38,496	-	38,496	
"	LeaSun Winion L.P.	//	ıı ,	-	39,902	12.47	39,902	
"	NFC Fund II L.P.	//	ıı ,	-	210,325	32.88	210,325	
"	Foryou Venture Capital L.P.	//	ıı ,	-	41,100	5.77	41,100	
"	Renaissance Capital Limited Partnership	//	"	-	112,228	12.82	112,228	
"	Lian Ding Capital Investments Limited Partnership	//	ıı ,	-	283,233	10.23	283,233	
"	NFC Fund III, L.P.	//	"	-	143,755	19.90	143,755	
Win Semiconductors Cayman Islands Co., Ltd.	Vanchip (Tianjin) Technology Co., Ltd./Stock	Client	"	1,800	435,121	0.43	435,121	
					1,836,406		1,836,406]
The Company	Sino-American Silicon Products Inc./Stock	None	Non-current financial assets at fair value through other comprehensive income	529	113,471	0.09	113,471	
"	Inventec Solar Energy Corporation/Stock	//	"	34,000	-	10.51	-	(Note 1)
"	CDIB Capital Creative Industries Limited/Stock	//	"	2,717	15,404	3.33	15,404	(Note 2)
"	MagiCap Venture Capital Co., Ltd./Preferred Stock A	//	"	543	12,195	18.28	12,195	
	New Future Capital Co., Ltd./Stock	//	"	8,900	80,456	15.87	80,456	
"	Barits Biofund Inc./Stock	//	"	2,200	22,682	1.10	22,682	(Note 3)
"	NFC I Renewable Power Co., Ltd./Stock	//	"	16,200	237,681	15.00	237,681	
"	Gogolook Co., Ltd./Stock	//	"	3,550	534,220	11.09	534,220	
Win Semiconductors Cayman Islands Co., Ltd.	Broadcom Ltd./Stock	Client	"	75	3,180,984	0.02	3,180,984	
WIN Venture Capital Corp.	MOAI Green Power Corporation/Stock	None	ıı ,	90	-	0.23	-	
"	Merit Biotech INC./Stock	<i>"</i>	"	1,320	-	2.93	-	(Note 4)
"	Winresp INC./Stock	<i>"</i>	"	2,896	-	11.71	-	
Phalanx Biotech Group, Inc.	BioGenius Biotech, Co., Ltd./Stock	<i>"</i>	"	72	752	18.65	752	
_					4,197,845		4,197,845	
								1

Note 1: Inventec Solar Energy Corporation had declared bankruptcy to the Company in December 2021. The relevant procedures on the declaration of bankruptcy was still in progress at the court as of March 31, 2024.

Note 2: The Board of Directors of CDIB Capital Creative Industries Limited had resolved to dissolve and liquidate the company in 2023. As of March 31, 2024, the company was still within the period of liquidation.

Note 3: On August, 2023, the shareholders' meeting approved a resolution to rename Grand Fortune Venture Corp. to Barits Biofund Inc.

Note 4: The Board of Directors of Merit Biotech INC. had resolved to dissolve and liquidate the company in 2017. As of March 31, 2024, the company was still within the period of liquidation.

Schedule D Information on acquisition of real estate with purchase amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

Name of			Transaction	R		Relationship with		If the counter-party is a related party, disclose the previous transfer information					
company	Name of property	Transaction date	amount	Status of payment	Counter-party	the Company	Owner	Relationship with the Company	Date of transfer	Amount	References for determining price	Purpose of acquisition	Others
The Company	Factory buildings	2021/4/6~2021/5/25	<i>))</i>	As of March 31, 2024, the price paid	-	-	N/A	N/A	N/A	N/A	Price negotiation	Operating	None
				\$1,345,045 thousand.	Contractors, Ltd.							purpose	
"	Factory buildings	2021/10/15		As of March 31, 2024, the price paid		-	N/A	N/A	N/A	N/A	Price negotiation	Operating	None
				\$1,520,258 thousand.	Contractors, Ltd.							purpose	
"	Factory buildings	2022/6/9		As of March 31, 2024, the price paid		-	N/A	N/A	N/A	N/A	Price negotiation	Operating	None
				\$225,377 thousand.	Contractors, Ltd.							purpose	

Schedule E Information regarding receivables from related-parties exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

Name of company	Name of counter-party	Relationship	Ending	Turnover O		verdue	Amounts received	Allowances	Remark
Name of company	Name of counter-party	Kelationship	balance	rate	Amount	Action taken	in subsequent period	for bad debts	Kemark
Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Affiliate	900,007	(Note 1)	-	-	-	-	(Note 2)
Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	Affiliate	1,457,373	(Note 1)	-	-	-	-	(Note 2)

Note 1: The ending balance was other receivables, which was not applicable for the calculation of turnover rate.

Note 2: The amount of the transaction had been offset in the consolidated financial statements.

Schedule F Business relationships and significant inter-company transactions:

(In thousands of New Taiwan Dollars)

			Nature of	Intercompany transactions					
Number	Name of company	Name of counter-party	relationship		Amount		Percentage of the		
(Note 1)	Trume of company	rune of counter party	(Note 2)		(Note 3)	Trading terms	consolidated net revenue or		
			(Note 2)		(Note 3)		total assets		
1	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	3	Other receivables due from related parties	900,007	no difference with non-related parties	1.39%		
2	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	3	Other payables due to related parties	900,007	no difference with non-related parties	1.39%		
1	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	3	Other receivables due from related parties	1,457,373	no difference with non-related parties	2.25%		
3	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	3	Other payables due to related parties	1,457,373	no difference with non-related parties	2.25%		

Note 1: Company numbering as follows:

Parent company -0

Subsidiary starts from 1

Note 2: The numbering of the relationship between transaction parties as follows:

Parent company to subsidiary – 1

Subsidiary to parent company - 2

Subsidiary to subsidiary—3

Note 3: The amount of the transaction had been offset in the consolidated financial statements.

Schedule G Information on investments:

The following is the information on investees as of March 31, 2024 (excluding information on investees in mainland China):

(In thousands of New Taiwan Dollars)

		Location		Original inv	estment amount	The ending balance at this period				lew Talwall	
Name of investor	Name of investee		Main businesses and products	The ending balance balance at the end at the beginning		Shares (in thousands)	Percentage of ownership	Carrying value	Net income (losses) of investee	Investment income (losses)	Remark
The Company	WIN SEMI. USA, INC.	California USA	Marketing	8,203	8,203	1,000	100.00%	(2,150)	2,062	2,062	(Note 1)
ll.	Win Semiconductors Cayman Islands Co., Ltd.	Cayman Islands	Investment activities	11,127,774	11,127,774	376,600	100.00%	8,891,200	(669,919)	(669,919)	(Note 1)
"	WIN Venture Capital Corp.	Taiwan	Investment activities	1,040,000	1,040,000	104,000	100.00%	1,052,332	1,083	1,083	(Note 1)
"	Phalanx Biotech Group, Inc.	Taiwan	Researching, manufacturing and selling of high-density gene chips and testing service	1,079,169	1,079,169	53,427	73.67%	399,582	(32,983)	(24,297)	(Note 1)
n,	WIN Chance Investment Corp.	Taiwan	Investment activities	830,000	830,000	87,350	100.00%	918,736	1,316	1,316	(Note 1)
n,	WIN Earn Investment Corp.	Taiwan	Investment activities	580,000	580,000	58,000	100.00%	486,094	824	824	(Note 1)
"	ITEQ Corporation	Taiwan	Manufactures and sells mass lamination boards, copper-clad laminates, prepreg, and electronic components	6,120,993	6,120,993	65,409	18.02%	7,884,510	153,612	10,836	
WIN Venture Capital Corp.	Phalanx Biotech Group, Inc.	Taiwan	Researching, manufacturing and selling of high-density gene chips and testing service	39,600	39,600	1,116	1.54%	25,752	(32,983)	(Note 2)	(Note 1)
n .	ITEQ Corporation	Taiwan	Manufactures and sells mass lamination boards, copper-clad laminates, prepreg, and electronic components	952,396	952,396	8,767	2.42%	977,271	153,612	(Note 2)	
Win Semiconductors Cayman Islands Co., Ltd.	Rainbow Star Group Limited	British Virgin Islands	Investment activities	62,920	62,920	38	49.30%	23,245	(24,734)	(Note 2)	1
"	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Cayman Islands	Investment activities	10,905,959	10,905,959	185,054	81.23%	5,179,804	(700,900)	(Note 2)	(Note 1)
Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Win Lux Biotech (Cayman Islands) Co., Ltd.	Cayman Islands	Investment activities	15,010	15,010	500	100.00%	12,013	(47)	(Note 2)	(Note 1)
"	i-Chainwin Technology Co., Ltd.	Taiwan	Information software services	220,000	220,000	22,000	100.00%	120,595	(3,014)	(Note 2)	(Note 1)
"	Win Lux Biotech Co., Ltd.	Taiwan	Biotechnology services and pharmaceutical testing	250,000	250,000	25,000	100.00%	62,463	(19,861)	(Note 2)	(Note 1)
Phalanx Biotech Group, Inc.	Phalanx Biotech Limited	Hong Kong	Investment activities	18,275	18,275	-	100.00%	4,165	731	(Note 2)	(Note 1)
"	PhalanxBio, Inc.	USA	Selling of high-density gene chip and testing service	208,110	208,110	2,550	100.00%	18	-	(Note 2)	(Note 1)
n n	Guzip Biomarkers Corporation	Taiwan	Development and sales of test reagents for endometrial cancer	81,727	81,727	14,238	100.00%	71,042	(623)	(Note 2)	(Note 1)
WIN Chance Investment Corp.	ITEQ Corporation	Taiwan	Manufactures and sells mass lamination boards, copper-clad laminates, prepreg, and electronic components	832,945	832,945	7,935	2.19%	913,679	153,612	(Note 2)	
WIN Earn Investment Corp.	ITEQ Corporation	Taiwan	Manufactures and sells mass lamination boards, copper-clad laminates, prepreg, and electronic components	568,005	568,005	4,230	1.17%	429,776	153,612	(Note 2)	

Note 1: The amount of the transaction had been offset in the consolidated financial statements.

Note 2: The share of profit (loss) of the investee company is not reflected herein as such amount is already included in the share of profit (loss) of the investor company.

Schedule H Information on investment in mainland China:

(i) The names of investees in mainland China, the main businesses and products, and other information:

(In thousands of New Taiwan Dollars)

Name of investee	Main businesses and products	Total amount of paid-in capital	Method of investment	Accumulated outflow of investment from Taiwan at the	Investmen	t flows	Accumulated outflow of investment from Taiwan at the	Net income (losses) of the investee	Direct/Indirect percentage of ownership by the	Investment income (losses) (Note 6)(Note 8)	Carrying value at the end of this period	Accumulated remittance of earnings in current	Remark
				beginning of this year	Outflow	Inflow	March 31, 2024	of the investee	Company	(11010 0)(11010 0)	(Note 7)	period	
Jiangsu Chainwin Kang Yuan Agricultural Development	Developing hog farming technology and trading	3,816,459	(Note 5)	3,309,022	-	-	3,309,022	(252,709)	81.23%	(252,709)	1,485,019	-	(Note 13)
Co., Ltd.													
Jiangsu Chainwin Agriculture and Animal Technology	Farm feed developing and trading	1,314,369	(Note 1)	1,291,505	-	-	1,291,505	(68,303)	81.23%	(68,303)	715,001	-	(Note 13)
Co., Ltd.													
Jiangsu CM/Chainwin Agriculture Development Co., Ltd.	Developing hog farming technology and trading	2,059,210	(Note 1)	1,122,874	-	-	1,122,874	(36,998)	39.80%	(18,129)	544,562	-	
Jiangsu Win Chance Agriculture Development Co., Ltd.	Developing hog farming technology and trading	610,094	(Note 4)	651,142	-	-	651,142	(7,413)	81.23%	(7,413)	225,382	-	(Note 13)
Jiangsu Merit/Cofcojoycome Agriculture Development Co., Ltd.	Developing hog farming technology and trading	-	(Note 1)	149,664	-	-	149,664	-	-	-	-	-	(Note 10)
Jiangsu Merit Runfu Agriculture Development Co., Ltd.	Developing hog farming technology and trading	-	(Note 3)	41,009	-	-	41,009	(85)	-	(85)	-	-	(Note 11)(Note 13)
Jiangsu Win Yield Agriculture Development Co., Ltd.	Developing hog farming technology and trading	2,655,955	(Note 1)	2,460,935	-	-	2,460,935	(236,769)	81.23%	(236,769)	1,341,107	-	(Note 13)
Jiangsu Win Shine Agriculture Development Co., Ltd.	Logistics management service	345,130	(Note 1)	85,170	-	-	85,170	(8,048)	81.23%	(8,048)	289,225	-	(Note 13)
Jiangsu Win Boutique Agriculture Development Co., Ltd.	Developing hog farming technology and trading	288,100	(Note 4)	-	-	-	-	(19,277)	81.23%	(19,277)	256,316	-	(Note 13)
Jiangsu Win Sunlight Agriculture Development Co., Ltd.	Developing hog farming technology and trading	288,100	(Note 4)	86,430	-	-	86,430	(12,103)	81.23%	(12,103)	268,226	-	(Note 13)
Jiangsu Win Honor Management Technology Co., Ltd.	Logistics management service	288,100	(Note 4)	-	-	-	-	(8,796)	81.23%	(8,796)	296,856	-	(Note 13)
Jiangsu Win Wonder Agriculture Development Co., Ltd.	Developing farming technology and trading	88,173	(Note 3)	-	-	-	-	(4,386)	81.23%	(4,386)	41,921	-	(Note 13)
Jiangsu Win Fortune Agriculture Development Co., Ltd.	Developing hog farming technology and trading	276,400	(Note 4)	221,120	-	-	221,120	(29,713)	81.23%	(29,713)	262,878	-	(Note 13)
Chainwin (Huaian) AIoT Co., Ltd.	Information software services	27,860	(Note 4)	27,860	-	-	27,860	(2,632)	81.23%	(2,632)	24,280	-	(Note 13)
Jiangsu Win Advance Bio-Assay Co., Ltd.	Biotechnology testing service	111,560	(Note 4)	-	-	-	-	(686)	81.23%	(686)	(6,022)	-	(Note 13)
Jiangsu Win Lux Biotech Co., Ltd.	Biotech research and development and bioassay	27,680	(Note 1)	27,680	-	-	27,680	627	81.23%	627	30,872	-	(Note 13)
Onearray Biotech (Kunshan) Co., Ltd.	Selling of high density gene chip and testing service	18,275	(Note 2)	18,275	-	-	18,275	730	75.21%	730	4,091	-	(Note 13)

(ii) Limitation on investment in mainland China:

(In thousands of Dollars)

Investor Company Name		cumulated Investment in mainland	Investme	ent Amounts	Upper Limit	
		China at the end	Authorized by Investment		on Investment	
		(Note 9)(Note 10)(Note 11)		sion, MOEA	(Note 12)	
The Company and subsidiaries		9,754,106		11,035,706	21 052 717	
The Company and subsidiaries	(USD	331,189)	(USD	344,866)	21,953,717	

- Note 1: The Group invested in mainland China companies through Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd., which is established in a third region.
- Note 2: The Group invested in mainland China companies through Phalanx Biotech Limited, which is established in a third region.
- Note 3: The Company invested in mainland China companies through Jiansu Win Chance Agriculture Development Co., Ltd.
- Note 4: The Company invested in mainland China companies through Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.
- Note 5: The Group co-invested in a company in mainland China through Chainwin Biotech Agrotech (Cayman Islands) Co., Ltd., which was established in a third region, and Jiangsu Win Sunlight Agriculture Development Co., Ltd.
- Note 6: The amount of net income (losses) was recognized based on the reviewed financial statements of the investee companies.
- Note 7: Carrying value as of March 31, 2024 was with reference to the amount recognized by the investment through subsidiaries to subsidiaries established in a third region.
- Note 8: Investment income (loss) recognized was translated into New Taiwan Dollars at the average exchange rate for the each month from January 1 to March 31, 2024.
- Note 9: The Group acquired Vanchip (Tianjin) Technology Co., Ltd. through a third region, wherein the outflow of investment from Taiwan amounted US\$9,383 thousand (NT\$261,420 thousand).
- Note10: Jiansu Merit/Cofcojoycome Agriculture Development Co., Ltd. had been liquidated on January 25, 2019. However, according to the regulation of Investment account.
- Note11: Jiangsu Merit Runfu Agriculture Development Co., Ltd. had been liquidated on March 22, 2024. However, according to the regulation of Investment Commission the remittance to mainland China amounting to US\$1,335 thousand (NT\$41,009 thousand) was included in the accumulated investment account.
- Note12: Amount of upper limit on investment was the higher between sixty percentage of total equity or total consolidated equity.
- Note13: The amount of the transaction and the ending balance had been offset in the consolidated financial statements.
 - (iii) Significant transactions: Please refer Schedule A, Schedule B, Schedule E and Schedule F.

Schedule I Information on major shareholders:

		(In shares)
Shareholding Shareholder's Name	Shares	Percentage
Cathay Life Insurance Co., Ltd.	22,698,000	5.35%